<!-- This content is only licensed for consumption by authorized users affiliated with PubMed Central. Usage by any individual not directly associated with PubMed Central is prohibited. -->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" id="b061309655" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Appl Mater Interfaces</journal-id><journal-id journal-id-type="iso-abbrev">ACS Appl Mater Interfaces</journal-id><journal-id journal-id-type="publisher-id">am</journal-id><journal-id journal-id-type="coden">aamick</journal-id><journal-title-group><journal-title>ACS Applied Materials &#x00026; Interfaces</journal-title></journal-title-group><issn pub-type="ppub">1944-8244</issn><issn pub-type="epub">1944-8252</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.acsami.org">www.acsami.org</self-uri></journal-meta>
<article-meta><article-id pub-id-type="pmid">40327818</article-id><article-id pub-id-type="pmc">PMC12100600</article-id>
<article-id pub-id-type="doi">10.1021/acsami.5c05429</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="document-subtype-name"><subject>Biological and Medical Applications of Materials and Interfaces</subject></subj-group></article-categories><title-group><article-title>Tailored
Mesoporous Silica Nanoparticles and the Chick
Chorioallantoic Membrane: A Promising Strategy and Model for Efficient
Blood-Brain Barrier Crossing</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e19-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7136686</contrib-id><name><surname>Lin</surname><given-names>Cong-Kai</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7561826</contrib-id><name><surname>Yang</surname><given-names>Yi-Shan</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6373450</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5473-9164</contrib-id><name><surname>Liu</surname><given-names>Tsang-Pai</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7561830</contrib-id><name><surname>Lin</surname><given-names>Jiunn-Chang</given-names></name><xref rid="aff3" ref-type="aff"/><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7561834</contrib-id><name><surname>Bupphathong</surname><given-names>Sasinan</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">758726</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4220-6408</contrib-id><name><surname>Tamanoi</surname><given-names>Fuyuhiko</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1841833</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5443-2632</contrib-id><name><surname>Chen</surname><given-names>Yi-Ping</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff5" ref-type="aff"/><xref rid="aff7" ref-type="aff"/></contrib><aff id="aff1">
<label>a</label>
<institution content-type="dept">Graduate
Institute of Biomedical Materials Tissue Engineering, College of Biomedical
Engineering</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">548311</institution-id><institution>Taipei Medical University</institution></institution-wrap>, <city>Taipei</city>
<postal-code>110</postal-code>, <country country="TW">Taiwan</country>
</aff><aff id="aff2">
<label>b</label>
<institution content-type="dept">Department
of Neurosurgery</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">63474</institution-id><institution>Taipei Medical University
Hospital</institution></institution-wrap>, <city>Taipei</city>
<postal-code>110</postal-code>, <country country="TW">Taiwan</country>
</aff><aff id="aff3">
<label>c</label>
<institution content-type="dept">Department
of Surgery</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">36897</institution-id><institution>MacKay Memorial Hospital</institution></institution-wrap>, <city>Taipei</city>
<postal-code>104</postal-code>, <country country="TW">Taiwan</country>
</aff><aff id="aff4">
<label>d</label>
<institution>MacKay Junior
College of Medicine, Nursing and Management</institution>, <city>New Taipei</city>
<postal-code>252</postal-code>, <country country="TW">Taiwan</country>
</aff><aff id="aff5">
<label>e</label>
<institution content-type="dept">Graduate
Institute of Nanomedicine and Medical Engineering, College of Biomedical
Engineering</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">38032</institution-id><institution>Taipei Medical University</institution></institution-wrap>, <city>Taipei</city>
<postal-code>110</postal-code>, <country country="TW">Taiwan</country>
</aff><aff id="aff6">
<label>f</label>
<institution content-type="dept">Institute
for Integrated Cell-Material Sciences, Institute for Advanced Study</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">12918</institution-id><institution>Kyoto University</institution></institution-wrap>, <city>Kyoto</city>
<postal-code>606-8501</postal-code>, <country country="JP">Japan</country>
</aff><aff id="aff7">
<label>g</label>
<institution content-type="dept">International
Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">38032</institution-id><institution>Taipei Medical University</institution></institution-wrap>, <city>Taipei</city>
<postal-code>110</postal-code>, <country country="TW">Taiwan</country>
</aff></contrib-group><author-notes><corresp id="cor1">
<label>*</label>Email: <email>haychen@tmu.edu.tw</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>06</day><month>5</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>21</day><month>5</month><year>2025</year></pub-date><volume>17</volume><issue>20</issue><fpage>29437</fpage><lpage>29454</lpage><history>
<date date-type="received"><day>17</day><month>3</month><year>2025</year></date>
<date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date>
<date date-type="rev-recd"><day>22</day><month>4</month><year>2025</year></date>
<date date-type="online"><day>06</day><month>5</month><year>2025</year></date>
</history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" content-type="AuthorChoicev2" start_date="2025-05-06"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2025-05-06">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><abstract><p>Crossing the blood-brain
barrier (BBB) remains a major challenge
for brain-targeted drug delivery. Mesoporous silica nanoparticles
(MSNs) with tunable size and surface properties are promising vehicles
for crossing the BBB. In this study, we explored the potential applications
of the chick chorioallantoic membrane (CAM) model in combination with
nanotherapeutics. We synthesized &#x0223c;25 nm MSNs and RITC-conjugated
MSNs (RMSNs) with short PEG chains and varying amounts of positively
charged molecules, specifically tertiary amine (polyethylenimine,
PEI) or quaternary amine (trimethylammonium, TA), to investigate the
positive charge effects on BBB penetration. Strongly positively charged
TA-modified RMSNs (s-RMSN@PEG/TA, where s denotes strongly positively
charged) effectively crossed the chick embryo BBB, whereas PEI-modified
RMSNs did not. Although the weakly positively charged formulation
(w-MSN@PEG/TA, where w denotes weakly positively charged) exhibited
higher Dox loading capacity and a faster release rate, s-MSN@PEG/TA
demonstrated superior BBB penetration and drug permeability. Consistent
with chick CAM results, RMSN@PEG/TA also penetrated the BBB in mice.
Long-chain PEG-modified RMSN@PEG/TA (RMSN@PEG<sub>(L)</sub>/TA, where
L denotes long-chain PEG) showed reduced BBB penetration due to steric
hindrance, possibly shielding TA molecules. This study highlights
the effectiveness of optimizing short PEG chain density and TA modification
for MSN-based BBB crossing without additional biological ligands.
Furthermore, the chick CAM model proves to be a valuable alternative
to mouse models for assessing BBB crossing of nanoparticles, offering
significant research opportunities.</p></abstract><abstract abstract-type="graphical"><graphic xlink:href="am5c05429_0009.jpg" position="float"/></abstract><abstract abstract-type="toc-graphic"><graphic xlink:href="am5c05429_0007.jpg" id="tgr1" position="float"/></abstract><kwd-group><kwd>blood-brain barrier</kwd><kwd>mesoporous silica nanoparticles</kwd><kwd>chick chorioallantoic membrane</kwd><kwd>PEG chain</kwd><kwd>surface charge</kwd><kwd>drug delivery</kwd></kwd-group><funding-group><award-group id="fnd-1"><funding-source>
<institution-wrap><institution>Taipei Medical University</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100004700</institution-id></institution-wrap>
</funding-source><award-id>108TMU-TMUH-22</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source>
<institution-wrap><institution>National Science and Technology Council</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100020950</institution-id></institution-wrap>
</funding-source><award-id>NSTC 112-2113-M-038-004</award-id></award-group></funding-group><funding-group><award-group id="fnd-3"><funding-source>
<institution-wrap><institution>National Science and Technology Council</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100020950</institution-id></institution-wrap>
</funding-source><award-id>NSTC 113-2124-M-038-002</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>am5c05429</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>am5c05429</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>ee8ad8a46de76edfb253e14e9708545ea3f713f00ccd5b9356f51ebd0e35ff5a</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>The blood-brain barrier
(BBB) serves as a critical interface between
neural tissues and circulating blood, functioning as a homeostatic
defense mechanism for the brain. Despite the prevalence of clinical
trials related to brain diseases, many of these efforts have encountered
limited success, primarily due to the impermeability of the BBB to
most therapeutic agents.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>,<xref rid="ref2" ref-type="bibr"/>
</named-content> This inherent restriction
poses a significant challenge to the delivery of drugs to the brain,
allowing only a minimal amount of therapeutic molecules to cross the
barrier.<xref rid="ref3" ref-type="bibr"/> Consequently, overcoming this
challenge and developing innovative delivery systems have become urgent
priorities in the treatment of brain-related diseases.</p><p>Nanoparticle-based
drug delivery systems (NDDS) have emerged as
a promising approach to enhance drug availability and facilitate the
traversal of the BBB, offering new opportunities for treating brain
disorders.<xref rid="ref4" ref-type="bibr"/> Various mechanisms are involved
in the transport of nanoparticles (NPs) across the BBB, including
passive and active targeting.<xref rid="ref5" ref-type="bibr"/> Among these,
size and surface charge are crucial factors influencing NPs transport
across the BBB and their interaction with brain cells.<named-content content-type="bibref-group">
<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref7" ref-type="bibr"/>
</named-content> Small-sized NPs are particularly efficient at crossing the BBB due
to their ability to pass through the tight junctions between endothelial
cells, which act as barriers to substance entry into the brain.<xref rid="ref8" ref-type="bibr"/> Additionally, smaller NPs exhibit improved diffusion
properties, allowing them to pass through the BBB and reach the desired
brain tissue.<named-content content-type="bibref-group">
<xref rid="ref9" ref-type="bibr"/>,<xref rid="ref10" ref-type="bibr"/>
</named-content> This emphasizes the importance
of NPs size as a critical factor in overcoming BBB barriers.</p><p>Positively charged NPs may enhance BBB crossing due to the unique
properties and charge selectivity of the BBB.<xref rid="ref11" ref-type="bibr"/> The BBB is composed of tightly packed endothelial cells connected
by tight junctions, creating a negative surface charge owing to the
presence of glycoproteins and other charged components on the cell
surfaces.<xref rid="ref12" ref-type="bibr"/> As a result, electrostatic
interactions between positively charged NPs and endothelial cells
can facilitate BBB crossing. Moreover, positively charged NPs can
undergo adsorptive-mediated transcytosis, a process in which they
adhere to the endothelial cell membrane and are subsequently transported
through the cell.<xref rid="ref13" ref-type="bibr"/> This mechanism allows
NPs to bypass the tight junctions between endothelial cells, favoring
efficient delivery to the brain. Research has shown that positively
charged NPs exhibit approximately 100 times greater permeability across
the BBB compared to their neutral counterparts.<xref rid="ref7" ref-type="bibr"/> Thus, the surface charge effect of NPs is of considerable
importance in the design of effective drug delivery systems across
the BBB.</p><p>When NPs are injected into the bloodstream, they undergo
rapid
adsorption of serum proteins onto their surfaces, forming a dynamic
layer known as the protein corona.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref15" ref-type="bibr"/>
</named-content> This phenomenon
is highly relevant in nanomedicine, as the protein corona can significantly
influence NP behavior, thereby affecting therapeutic efficacy. The
surface properties of NPs play a pivotal role in the formation of
protein coronas, directly impacting therapeutic outcomes. Polyethylene
glycol (PEG) coating is a common strategy in NDDS to enhance NP performance,
including extending circulation time, reducing immune system recognition,
enhancing bioavailability, and mitigating the protein corona effect.<xref rid="ref16" ref-type="bibr"/> However, an excessive PEG chain length can lead
to steric hindrance, potentially shielding ligands or molecules on
the NP surfaces, which may impede their interaction with BBB receptors
or transporters and hinder effective BBB penetration.<xref rid="ref17" ref-type="bibr"/> Therefore, optimizing the PEG chain length and density
is crucial in designing NPs to efficiently penetrate the BBB. Understanding
and managing the protein corona effect, particularly concerning PEG
coating, is vital for enhancing the success of NDDS in treating brain
diseases.</p><p>To gain a more comprehensive understanding of BBB
function and
dysfunction, various in vitro and in vivo models have been employed.
In vitro assays, such as transwell assays using cultured rodent or
nonhuman mammalian cells, are used to measure the permeability of
substances through a monolayer of BBB endothelial cells, allowing
researchers to assess BBB tightness.<named-content content-type="bibref-group">
<xref rid="ref18" ref-type="bibr"/>,<xref rid="ref19" ref-type="bibr"/>
</named-content> While in vitro
models offer precise control of experimental conditions, high throughput,
and low ethical concerns, they fall short of fully replicating the
complexity of the BBB in living organisms.<named-content content-type="bibref-group">
<xref rid="ref20" ref-type="bibr"/>,<xref rid="ref21" ref-type="bibr"/>
</named-content> In contrast, in vivo models, such as those using zebrafish (Danio
rerio) or mice, provide valuable insights into physiological relevance,
disease states, pathological changes, therapeutic outcomes, and BBB
integrity within a living organism.<named-content content-type="bibref-group">
<xref rid="ref22" ref-type="bibr"/>&#x02212;<xref rid="ref23" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref24" ref-type="bibr"/>
</named-content> However, these models
come with strict ethical concerns, high production costs, and interspecies
variability.<xref rid="ref25" ref-type="bibr"/> Thus, a balanced approach
that combines the strengths of both in vitro and in vivo models is
crucial for advancing BBB-related research and treatment development.</p><p>A 2022 review published in ACS Nano by Liang et al. highlighted
the chick chorioallantoic membrane (CAM) model as a valuable bridge
between in vitro and in vivo studies.<xref rid="ref26" ref-type="bibr"/> Their work emphasized the chick CAM&#x02019;s capacity to accelerate
the validation and qualification of NPs for in vivo investigations,
showcasing its potential as an alternative in vivo model. Previous
reports have indicated that the BBB integrity of the chick CAM matures
around embryonic day 12, at which point the tight junctions between
endothelial cells strengthen, restricting the passage of various substances
similar to the mature BBB of the mammalian brain.<xref rid="ref27" ref-type="bibr"/> Despite the inherent differences from the human BBB, the
chick CAM model offers a cost-effective and efficient alternative
to traditional mouse models, providing valuable contributions to specific
aspects of BBB research, particularly in drug delivery and high-throughput
screening of BBB-penetrating drugs. These findings suggest that the
chick CAM model could serve as a reliable tool for studying BBB permeability
and substance passage, making it a promising alternative to conventional
mouse models in BBB research.</p><p>Mesoporous silica nanoparticles
(MSNs) offer a highly tunable platform
for the controlled delivery of therapeutics, owing to their adjustable
pore size, large surface area, and versatile surface functionalization.
These characteristics make MSNs particularly attractive for central
nervous system (CNS) drug delivery, where precise targeting and protection
of labile therapeutic agents are essential. In recent years, MSN-based
drug delivery systems have been developed for the treatment of neurodegenerative
diseases such as Alzheimer&#x02019;s disease (AD), Parkinson&#x02019;s
disease (PD), and amyotrophic lateral sclerosis (ALS). For instance,
Gonz&#x000e1;lez et al. designed an MSN-based nanocarrier coloaded
with leptin and pioglitazone, which was able to cross the BBB and
demonstrated neuroprotective effects in an ALS mouse model by reducing
inflammation and oxidative stress.<xref rid="ref28" ref-type="bibr"/> Similarly,
other studies have employed MSNs to deliver therapeutic agents, such
as curcumin or fluorescent probes of SZIs, into the brains of AD mice,
aiming to successfully modulate neuroinflammation or facilitate amyloid-beta
imaging in vivo.<named-content content-type="bibref-group">
<xref rid="ref29" ref-type="bibr"/>,<xref rid="ref30" ref-type="bibr"/>
</named-content> Collectively, these studies underscore
the promise of MSNs as versatile nanocarriers for addressing the complex
challenges of neurodegenerative disease therapy. Additionally, Brinker
et al. recently demonstrated the use of tailored MSNs by integrating
the CAM model to directly observe their in vivo behavior, including
selective leukemia cell targeting, vascular margination, circulation
dynamics, stability, and reduced endothelial binding after intravenous
injection.<named-content content-type="bibref-group">
<xref rid="ref31" ref-type="bibr"/>&#x02212;<xref rid="ref32" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref33" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref34" ref-type="bibr"/>
</named-content> The CAM model enables high-resolution, real-time imaging of MSN
interactions with tissues and cells in a live system, providing a
cost-effective and accessible platform for assessing nanocarrier fate
in vivo.</p><p>In this study, we developed 25 nm MSNs functionalized
with either
positively charged tertiary amine (polyethylenimine, PEI) or quaternary
amine (trimethylammonium, TA) molecules, along with polyethylene glycol
(PEG), to investigate the effects of surface charge and PEG chain
length on cellular internalization, BBB penetration, and drug delivery
efficacy (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>).
Our findings revealed that RITC-conjugated MSNs (RMSNs) functionalized
with short PEG (M.W. 459&#x02013;591) and TA (denoted RMSN@PEG/TA)
showed dose-dependent cellular uptake and no cytotoxicity, making
them favorable for therapeutic applications. In contrast, RMSNs modified
with short PEG and PEI (denoted RMSN@PEG/PEI) exhibited significantly
higher cytotoxicity, likely due to the inherent toxicity of PEI, despite
better cellular uptake. RMSN@PEG/TA demonstrated improved BBB permeability
without compromising BBB integrity. In comparison, RMSN@PEG/PEI failed
to achieve significant BBB crossing, highlighting that TA was crucial
for facilitating MSN penetration across the BBB. Brain imaging and
silicon content analysis revealed higher accumulation of s-RMSN@PEG/TA
(s indicated stronger positive charge) in chick brain tissues, indicating
superior BBB penetration compared to w-RMSN@PEG/TA (w indicated weaker
positive charge). Additionally, Dox-loaded MSN@PEG/TA showed dose-dependent
cytotoxicity in U87 glioma cells, confirming their therapeutic potential.
Dox-loaded w-MSN@PEG/TA (Dox@w-MSN@PEG/TA) exhibited efficient drug
loading and a pH-responsive release profile, with accelerated release
under acidic conditions (pH 5.5), characteristic of tumor environments.
Despite the lower Dox drug loading capacity of s-MSN@PEG/TA, its enhanced
surface charge facilitated more efficient BBB crossing and delivery
of Dox to brain tissues, achieving significantly higher brain accumulation
compared to free Dox and Dox@w-MSN@PEG/TA. The BBB penetration ability
was compromised when TA molecules were hindered by long PEG chains
(M.W. One k) in RMSN surface modification (denoted RMSN@PEG<sub>(L)</sub>/TA, L stands for long-chain). Hence, we demonstrated that the MSN
with optimized short PEG density can retain the advantages of PEG
while preserving the functionality of TA, facilitating effective BBB
crossing. This straightforward design strategy based on TA modification
and the optimization of short PEG chains, enables MSNs to cross the
BBB without the need for additional BBB-penetrating ligands.</p><fig position="float" id="sch1" fig-type="scheme"><label>1</label><caption><title>Schematic
Representation of 25 nm MSNs Functionalized with Positively
Charged Tertiary Amine (PEI) or Quaternary Amine (TA) and Polyethylene
Glycol (PEG) to Examine the Impact of Surface Charge and PEG Chain
Length on Cellular Uptake, BBB Penetration, and Drug Delivery Efficacy</title></caption><graphic xlink:href="am5c05429_0006" id="gr1" position="float"/></fig><p>Additionally, although the chick CAM model is
well-established
in tumor and angiogenesis research,<named-content content-type="bibref-group">
<xref rid="ref35" ref-type="bibr"/>,<xref rid="ref36" ref-type="bibr"/>
</named-content> its application
in BBB research remains limited yet holds significant potential. In
this study, the chick CAM model effectively mimicked the intact BBB
of mammalian systems, with trypan blue staining confirming BBB maturity
on embryonic day 15. The consistency between chick CAM and mouse models
supports the use of chick CAM as a reliable and cost-effective alternative
in vivo model for assessing BBB permeability.</p></sec><sec id="sec2"><label>2</label><title>Materials and Methods</title><sec id="sec2.1"><label>2.1</label><title>Chemicals
and Reagents</title><p>All reagents
were obtained from commercial suppliers and used without further purification.
Doxorubicin (Dox), sodium bicarbonate (&#x02265;99.7%), Rhodamine B
isothiocyanate (RITC), and Fluorescein Isothiocyanate-Dextran (FITC-Dextran,
M.W. 40 kDa) were purchased from Sigma-Aldrich (Germany). Ammonium
hydroxide solution (28.0&#x02013;30.0% in water), cetyltrimethylammonium
bromide (CTAB, 99%+), tetraethyl orthosilicate (TEOS, 98%), and 3-Aminopropyltrimethoxysilane
(APTMS, 95%) were sourced from Acros Organics (Germany). 2-[Methoxy&#x000ad;(polyethyleneoxy)&#x000ad;6&#x02013;9propyl]&#x000ad;trimethoxysilane
(PEG-silane, M.W. 459&#x02013;591 g/mol), 2-[Methoxy&#x000ad;(polyethyleneoxy)&#x000ad;21&#x02013;24propyl]&#x000ad;trimethoxysilane
(PEG<sub>(L)</sub>-silane, M.W. One k g/mol, where L stands for long
chain), N-trimethoxysilylpropyl-N,N,N-trimethylammonium chloride (TMAC-silane,
50% in methanol, M.W. 257.83), and trimethoxysilylpropyl-modified
(polyethyleneimine) (PEI-Silane, 50%, M.W. 1500&#x02013;1800) were
obtained from Gelest (Morrisville, PA, USA). Trypan blue (0.4%) was
purchased from Thermo Fisher Scientific (Waltham, MA, USA). Fetal
bovine serum (FBS) and penicillin were obtained from HyClone Laboratories
(Logan, UT, USA). Cell Counting Kit-8 (CCK-8) was acquired from Dojindo
Laboratories (Japan).</p></sec><sec id="sec2.2"><label>2.2</label><title>Preparation of Mesoporous
Silica Nanoparticles
(MSNs) and RITC-Conjugated MSNs (RMSNs)</title><p>Typically, 0.29 g
of CTAB was dissolved in 150 mL of a 0.128 M aqueous ammonium hydroxide
solution. The resulting mixture was sealed with parafilm and incubated
in a water bath at 60 &#x000b0;C for 15 min with continuous stirring.
Subsequently, 2 mL of 0.88 M TEOS predissolved in ethanol was gradually
added dropwise to the solution under continuous stirring. For the
synthesis of RITC-conjugated MSNs (RMSNs), 8 mg of RITC was dissolved
in 5 mL of 99.5% ethanol and stirred for 15 min. Subsequently, 10
&#x003bc;L of APTMS was added to the solution, and the mixture was stirred
under dark conditions at room temperature for 24 h to produce preconjugated
RITC-APTMS before adding 2 mL of 0.88 M TEOS solution.</p><p>After
1 h, a mixture of PEG-silane or PEG<sub>(L)</sub>-silane (1.07 mmol)
and TA-silane (0.54 mmol for weak positive charge and 2.2 mmol for
strong positive charge) or PEI-silane (0.83 &#x003bc;mol for weaker
positive charge and 5.57 &#x003bc;mol for stronger positive charge)
was introduced to the solution. The mixture was gently stirred for
1 h and then the solution was aged and concentrated to one-third of
its original volume at 60 &#x000b0;C for 24 h. The obtained NPs were
then subjected to hydrothermal treatment at 70 &#x000b0;C for 24 h, followed
by a second treatment at 90 &#x000b0;C for an additional 24 h. The surfactants
were removed by hydrochloric acid extraction at 60 &#x000b0;C, and the
NPs were washed twice with ethanol using a cross-flow filtration system.
Finally, template-removed RMSNs with a diameter of 25 nm, carrying
different amounts of positively charged ligands of polyethyleneimine
(PEI) or a quaternary amine group (TA-silane) were obtained, including
stronger positive charges (denoted s-RMSN@PEG/PEI and s-RMSN@PEG/TA)
and weaker positive charges (denoted w-RMSN@PEG/PEI and w-RMSN@PEG/TA),
and stored in 95% ethanol.</p></sec><sec id="sec2.3"><label>2.3</label><title>Characterization of MSNs</title><p>The morphology
and mesoporous structural features of the RMSNs were characterized
using transmission electron microscopy (TEM, HITACHI HT7700, Tokyo,
Japan) operated at an acceleration voltage of 60 kV. TEM images were
analyzed with Scanpro software to determine the size distribution
of the MSNs. The surface area and pore size of the NPs were measured
using the Brunauer&#x02013;Emmett&#x02013;Teller (BET) and Barrett&#x02013;Joyner&#x02013;Halenda
(BJH) calculation methods based on nitrogen adsorption&#x02013;desorption
isotherms (Micromeritics ASAP 2020, USA). The mean hydrodynamic size
of the NPs was determined using dynamic light scattering (DLS, Zetasizer
Nano ZS90, Malvern Instruments, Worcestershire, UK). Zeta potential
measurements were conducted to assess the surface charge of the NPs
through electrophoretic mobility, also using the Zetasizer Nano ZS90.
Elemental analysis for nitrogen, carbon, sulfur, and hydrogen (NCSH)
content was performed using an Elementar Vario EL cube instrument
(Germany), providing the detailed elemental composition of the RMSNs.
The chemical functional groups present in the various MSNs were identified
using FTIR spectroscopy (Nicolet iS10 FTIR Spectrometer, Thermo Fisher
Scientific).</p></sec><sec id="sec2.4"><label>2.4</label><title>Cell Culture</title><p>The
human glioma U87-MG
cell line was maintained in Dulbecco&#x02019;s modified Eagle&#x02019;s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100
units/mL penicillin, 100 &#x003bc;g/mL streptomycin, 1 mM sodium pyruvate,
and 1 mM nonessential amino acids. The cells were incubated at 37
&#x000b0;C in a humidified atmosphere containing 5% CO2. Subculturing
was performed when the cells reached approximately 80% confluence.</p></sec><sec id="sec2.5"><label>2.5</label><title>Cellular Uptake</title><p>U87-MG cells were
seeded in 6-well plates at a density of 2 &#x000d7; 10<sup>5</sup> cells
per well and cultured overnight. Subsequently, RMSNs were added to
each well at the indicated concentrations (250, 500, 750, and 1000
&#x003bc;g/mL) in DMEM complete medium and incubated for an additional
24 h. The cellular uptake of RMSNs in U87-MG cells was imaged under
an inverted fluorescence microscope (OPTIKA IM-3FL4, Italy) and quantified
using flow cytometry by detecting the RITC fluorescence signals, respectively.</p></sec><sec id="sec2.6"><label>2.6</label><title>Cytotoxicity Assay</title><p>U87-MG cells were
seeded in 96-well plates at a density of 1 &#x000d7; 10<sup>4</sup> cells
per well in DMEM complete medium and incubated for 24 h. Following
different RMSNs treatments at various concentrations (1, 2.5, 5, 10,
and 20 &#x003bc;g/&#x003bc;L) for an additional 24 h, cells were treated
with Cell Counting Kit-8 (CCK-8, Dojindo, Japan) for an additional
4 h. The absorbance of each well was then measured at 450 nm using
a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA) to
assess cell viability.</p><p>Preparation of Dox-Loaded MSNs: 20 mg
of MSN@PEG/TA (without RITC conjugation) was dispersed in 400 &#x003bc;L
of 0.1 M NaHCO<sub>3</sub> and incubated for 30 min, followed by washing
twice with double-distilled (dd) H<sub>2</sub>O. The washed MSN@PEG/TA
was redispersed in 1 mL ddH<sub>2</sub>O and added to 1.427 mg Dox
dissolved in 2 mL ddH<sub>2</sub>O. The mixture was incubated in the
dark at 25 &#x000b0;C for 1 h with gentle agitation and centrifuged at
3500 rpm using a Vivaspin-20-centrifugal-concentrator, followed by
washing with ddH<sub>2</sub>O to eliminate any remaining unloaded
Dox. The concentration of unloaded Dox was determined by measuring
its fluorescence intensity with excitation and emission wavelengths
set at 480 and 560 nm, respectively</p><p>The Dox loading efficiency
(%) and loading amount (%) of NPs were
calculated using the following equations:<disp-formula id="ueq1">
<alternatives><graphic xlink:href="am5c05429_m001.jpg" position="float"/><mml:math id="d1e482" display="block"><mml:mi>loading</mml:mi><mml:mspace width="0.25em"/><mml:mi>efficiency</mml:mi><mml:mspace width="0.25em"/><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">weight</mml:mi><mml:mspace width="0.25em"/><mml:mi>of</mml:mi><mml:mspace width="0.25em"/><mml:mi>Dox</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>Dox</mml:mi><mml:mo>@</mml:mo><mml:mi>MSN</mml:mi><mml:mo>@</mml:mo><mml:mi>PEG</mml:mi><mml:mo>/</mml:mo><mml:mi>TA</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">weight</mml:mi><mml:mspace width="0.25em"/><mml:mi>of</mml:mi><mml:mspace width="0.25em"/><mml:mi>total</mml:mi><mml:mspace width="0.25em"/><mml:mi>Dox</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:math></alternatives>
</disp-formula>
<disp-formula id="ueq2">
<alternatives><graphic xlink:href="am5c05429_m002.jpg" position="float"/><mml:math id="d1e529" display="block"><mml:mi>loading</mml:mi><mml:mspace width="0.25em"/><mml:mi>amount</mml:mi><mml:mspace width="0.25em"/><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">weight</mml:mi><mml:mspace width="0.25em"/><mml:mi>of</mml:mi><mml:mspace width="0.25em"/><mml:mi>Dox</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>Dox</mml:mi><mml:mo>@</mml:mo><mml:mi>MSN</mml:mi><mml:mo>@</mml:mo><mml:mi>PEG</mml:mi><mml:mo>/</mml:mo><mml:mi>TA</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">weight</mml:mi><mml:mspace width="0.25em"/><mml:mi>of</mml:mi><mml:mspace width="0.25em"/><mml:mi>Dox</mml:mi><mml:mo>@</mml:mo><mml:mi>MSN</mml:mi><mml:mo>@</mml:mo><mml:mi>PEG</mml:mi><mml:mo>/</mml:mo><mml:mi>TA</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:math></alternatives>
</disp-formula>
</p></sec><sec id="sec2.7"><label>2.7</label><title>In Vitro Dox Release Profile</title><p>0.5
mL of Dox and Dox-loaded MSNs suspension at a concentration of 0.2
mg/mL were enclosed in a dialysis membrane with a molecular weight
cutoff of 12&#x02013;14 kDa. The dialysis membrane was then immersed
in 1.7 mL of phosphate-buffered saline (PBS) at either pH 7.4 or pH
5.5 and maintained at 37 &#x000b0;C with gentle shaking. At predetermined
time intervals, 1 mL samples of the released Dox were collected and
analyzed using a fluorescence spectrometer (JASCO FP-8500, UK) at
an excitation wavelength of 480 nm and an emission wavelength of 560
nm. The concentration of released Dox was determined by referencing
a previously established calibration curve for Dox in PBS at both
pH 7.4 and pH 5.5.</p></sec><sec id="sec2.8"><label>2.8</label><title>Western Blot Analysis</title><p>Following NP
treatment, cells were lysed using RIPA buffer supplemented with protease
inhibitors and incubated on ice for 2 h. The lysates were then centrifuged
to collect the supernatant containing the extracted proteins. The
protein concentration in the supernatant was determined using the
Bradford protein assay. Subsequently, 20 &#x003bc;g of protein extract
were separated by electrophoresis on a 10% SDS-PAGE gel and then transferred
to a polyvinylidene fluoride (PVDF) membrane (EMD Millipore, Merck).
The PVDF membrane was blocked in PBS containing 0.1% Tween 20 (PBS-T)
with 5% (w/v) BSA for 1 h and then washed three times with PBS-T.
Primary antibodies against p-p38 (sc-17852-R, Santa Cruz Biotechnology,
USA), HMGB1 (ab227168, abcam, UK), and &#x003b1;-tubulin (sc-5286, Santa
Cruz Biotechnology, USA) were incubated with the PVDF membrane at
4 &#x000b0;C overnight with gentle rocking. After washing three times
with TBS-T, the membrane was further incubated with an HRP-conjugated
secondary immunoglobulin G antibody (Santa Cruz Biotechnology, USA)
in TBS-T containing 5% (w/v) bovine serum albumin (BSA) for 2 h at
room temperature. Finally, signals corresponding to the protein bands
were visualized using an enhanced chemiluminescent substrate kit (Amersham
Pharmacia Biotech, GE Healthcare, Bucks, UK) according to the manufacturer&#x02019;s
protocol.</p></sec><sec id="sec2.9"><label>2.9</label><title>BBB Model of Chick CAM and BBB Integrity Measurement</title><p>Fertilized eggs were purchased from JD-SPF Biotech (Taiwan) and
placed in an incubator at 37 &#x000b0;C with 70% humidity. To assess
BBB integrity in chick brains, trypan blue staining was used. On embryonic
day 13 or 16, a small hole with a diameter of 5 mm was created in
the eggshell for intravenous injection. Subsequently, 50 &#x003bc;L
of 0.4% trypan blue solution was injected into the chick CAM using
a 31G needle for 24 h. Finally, chick embryos were euthanized and
perfused with normal saline containing 0.15% EDTA, and the brains
and major organs (heart, liver, spleen, lung, and kidney) were then
harvested. Photographs of the trypan blue staining distribution in
the tissues were captured. Additionally, the collected organs were
fixed in 4% formaldehyde and embedded in optimal cutting temperature
(OCT) for subsequent frozen sectioning. The distribution of trypan
blue was imaged under a fluorescence microscope by capturing the red
fluorescence signals emitted by trypan blue with an excitation wavelength
of 633 nm.</p></sec><sec id="sec2.10"><label>2.10</label><title>Brain Imaging Observation</title><p>The chick
CAM was euthanized 24 h after the intravenous injection of either
RMSNs (at concentrations equivalent to Dox loaded MSNs), Dox alone
(0.03 mg/egg), or Dox loaded MSNs (at concentrations equivalent to
Dox alone) on embryonic day 15 and the brain was excised. Images of
RMSNs and Dox distribution were obtained with an IVIS imaging system
(IVIS Lumina III XRMS), capturing the fluorescence signals of RITC
at an excitation wavelength of 580 nm and an emission wavelength of
620 nm, or Dox an excitation wavelength of 480 nm and an emission
wavelength of 590 nm. The radiant efficiency, defined as fluorescence
intensity/area/time, was analyzed using the IVIS imaging software
with the region of interest (ROI) tool. To visualize blood vessels,
50 &#x003bc;L of fluorescein isothiocyanate-dextran (FITC-dextran) at
2.5 mg/mL was intravenously injected 24 h post-treatment (embryonic
day 16). After injection, the skull and dura mater of the brain were
carefully removed, and brain images were photographed using a two-photon
high-resolution microscope (Zeiss LSM 7 MP, Germany).</p></sec><sec id="sec2.11"><label>2.11</label><title>ICP-MS/MS Analysis</title><p>The Si content
in the brain of chick CAM was quantitatively determined using ICP-MS/MS
(Agilent 8900 ICP-MS/MS, USA). Briefly, fresh brains were weighed
and subsequently subjected to digestion using a 1600 W microwave (95
&#x000b0;C for 20 min, 180 &#x000b0;C for 15 min, and 200 &#x000b0;C for 15
min) in a 1:1:1 mixture of H<sub>2</sub>O/HF/HNO<sub>3</sub>. The
resulting digested samples were analyzed by ICP-MS/MS. Si concentration
was determined based on a calibration curve prepared with Si standards
in a concentration range of 0&#x02013;200 &#x003bc;g/L. The Si content
was reported as nanograms of Si per milligram of brain tissue.</p></sec><sec id="sec2.12"><label>2.12</label><title>Tissue Distribution of RMSNs and Dox</title><p>After 24 h of
treatment, chick embryos were humanely sacrificed,
and their brains were collected for frozen sectioning. The distribution
of RMSNs and Dox released from Dox-loaded MSNs was assessed using
confocal microscopy (Leica Stellaris 8 Confocal Microscope, Germany).
Red fluorescence signals from RITC (excitation: 580 nm; emission:
620 nm) and Dox (excitation: 480 nm; emission: 590 nm) were captured.
DAPI staining was performed to visualize cell nuclei. The percentage
of Dox-positive cells was quantified using TissueQuest software (TissueGnostics,
Vienna, Austria), which measures the fluorescence intensity of Dox
relative to DAPI.</p></sec><sec id="sec2.13"><label>2.13</label><title>In Vivo Dox Permeability</title><p>Collected
brains were homogenized using Precellys Homogenizers (Bertin Technologies,
France). Tissue samples were homogenized with acidified methanol (50%
methanol in 0.3 N HCl) and centrifuged at 24,000 &#x000d7; g for 10 min
at 4 &#x000b0;C. The fluorescence intensity of the resulting supernatant
was measured using a fluorescence spectrometer (JASCO FP-8500, UK)
with excitation and emission wavelengths set at 480 and 560 nm, respectively.
The concentration of Dox in the brain was determined using a calibration
curve established with Dox standards in a concentration range of 0&#x02013;1000
ng/L. The drug permeability was calculated using the formula shown
below:<disp-formula id="ueq3">
<alternatives><graphic xlink:href="am5c05429_m003.jpg" position="float"/><mml:math id="d1e615" display="block"><mml:mi mathvariant="normal">drug</mml:mi><mml:mspace width="0.25em"/><mml:mi>permeability</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>measured</mml:mi><mml:mspace width="0.25em"/><mml:mi>Dox</mml:mi><mml:mspace width="0.25em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>mg</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>Dox</mml:mi><mml:mo>@</mml:mo><mml:mi>NPs</mml:mi><mml:mspace width="0.25em"/><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.25em"/><mml:mi>mg</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:math></alternatives>
</disp-formula>
</p></sec><sec id="sec2.14"><label>2.14</label><title>Brain Distribution of
RMSNs in Mice</title><p>Male BALB/c mice, aged 12 to 14 weeks, were
purchased from BioLASCO
Experimental Animal Center (BioLASCO, Taipei, Taiwan) and housed under
specific pathogen-free (SPF) conditions. All procedures were conducted
in accordance with the guidelines of the Laboratory Animal Center
of Taipei Medical University. The mice were administered an intravenous
injection of NPs at a dosage of 200 mg/kg body weight. After 24 h
of treatment, the distribution of s-RMSN@PEG/PEI, s-RMSN@PEG/TA, and
s-RMSN@PEG<sub>(L)</sub>/TA in the brain was visualized using an IVIS
imaging system (IVIS Lumina III XRMS), capturing the RITC fluorescence
signals with an excitation wavelength of 580 nm and an emission wavelength
of 620 nm.</p></sec><sec id="sec2.15"><label>2.15</label><title>Statistical Analysis</title><p>Statistical
analysis was performed using GraphPad Prism 6 software (GraphPad Software,
Inc., San Diego, CA, USA). All experiments were independently conducted
at least three times, and the results are expressed as mean &#x000b1;
standard deviation (SD). Statistical significance between different
groups was compared using Student&#x02019;s <italic toggle="yes">t</italic> test.
A p-value of &#x0003c;0.05 was considered statistically significant, with
significance levels denoted as follows: *<italic toggle="yes">p</italic> &#x0003c; 0.05,
**<italic toggle="yes">p</italic> &#x0003c; 0.01, ***<italic toggle="yes">p</italic> &#x0003c; 0.001,
and ****<italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Preparation and Characterization of Various
Types of MSNs</title><p>PEGylation has emerged as a promising approach
to enhance the dispersity and stability of NPs in physiological environments.
Additionally, it extends the retention time of NPs in the bloodstream
and mitigates the serum protein corona effect. Positively charged
NPs offer advantages such as improved cellular uptake and enhanced
ability to cross the BBB. In this study, we synthesized MSNs with
a small size of 25 nm and focused on evaluating the impact of surface
properties and charge effects on BBB penetration. Four types of 25
nm MSNs were obtained by tailoring the PEG (M.W. 459&#x02013;591) content
and incorporating varying amounts of two positively charged molecules:
polyethyleneimine (PEI, M.W. 1500&#x02013;1800) and a quaternary amine
group (TA-silane, M.W. 257.83). Based on their surface characteristics,
these MSNs were categorized into strong (designated as s-MSN@PEG/PEI
and s-MSN@PEG/TA) and weak (designated as w-MSN@PEG/PEI and w-MSN@PEG/TA)
groups (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>a).</p><fig position="float" id="fig1" fig-type="figure"><label>1</label><caption><p>Physical
and chemical properties of various positively charged
MSNs. (a) Schematic illustration depicting the structural features
of different MSNs. (b) TEM images and size distribution histograms
of MSNs. Scale bar: 100 nm. (c) Zeta potential measurements of MSNs.
(d) DLS analysis showing the size distribution of MSNs in ddH<sub>2</sub>O and PBS. (e) Nitrogen adsorption&#x02013;desorption isotherms
and the corresponding pore size distribution plot of MSNs.</p></caption><graphic xlink:href="am5c05429_0001" id="gr2" position="float"/></fig><p>As depicted in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>b, all MSNs exhibited a uniform morphology
and well-defined
mesoporous structure, as observed in the transmission electron microscopy
(TEM) images. Zeta potential measurements (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>c) revealed that the surface charges of w-MSN@PEG/TA
and w-MSN@PEG/PEI were 9.1 &#x000b1; 1.08 mV and 13.6 &#x000b1; 1.70 mV,
respectively. In contrast, s-MSN@PEG/TA and s-MSN@PEG/PEI exhibited
stronger positive charges of 18.1 &#x000b1; 1.10 mV and 19.1 &#x000b1; 0.75
mV, respectively. The increased positive surface charges of s-MSN@PEG/TA
and s-MSN@PEG/PEI were attributed to the higher ratios of positively
charged TA or PEI molecules conjugated to the MSNs. Dynamic light
scattering (DLS) measurements indicated that the MSNs were well-suspended
with particle sizes ranging from 38 to 44 nm in both water and PBS
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>d). Elemental
analysis provided the atomic percentages of carbon (C), hydrogen (H),
and nitrogen (N) for the different MSNs, as summarized in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Table S1</ext-link>. Notably, s-MSN@PEG/TA, with a higher
proportion of TA modification, exhibited a greater nitrogen content
compared to w-MSN@PEG/TA. Similar trends were observed for s-MSN@PEG/PEI
and w-MSN@PEG/PEI with varying ratios of PEG and PEI. The typical
characteristics of mesoporous materials, such as a type IV isotherm
with a hysteresis loop, surface area (<italic toggle="yes">S</italic>
<sub>BET</sub>), and pore diameter (DBJH), were measured using nitrogen adsorption&#x02013;desorption
isotherms (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>e). All the basic characterization of various MSNs is summarized
in <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>. Ultimately,
we successfully synthesized 25 nm PEGylated MSNs with distinct surface
charges and positively charged ligands (PEI and TA). This study investigates
the charge effects of these various MSNs on BBB penetration, demonstrating
their potential as carriers for drug delivery.</p><table-wrap position="float" id="tbl1"><label>1</label><caption><title>Basic Characterization of the Various
MSNs</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th align="center">&#x000a0;</th><th align="center" char="&#x000b1;">&#x000a0;</th><th colspan="2" align="center" char="&#x000b1;">
<bold>size (nm)</bold>
<xref rid="t1fn1" ref-type="table-fn"/>
<hr/></th><th align="center" char="&#x000b1;">&#x000a0;</th><th align="center" char=".">&#x000a0;</th><th align="center" char=".">&#x000a0;</th></tr><tr><th align="center">
<bold>sample</bold>
</th><th align="center" char="&#x000b1;">
<bold>average
size from TEM (nm)</bold>
</th><th align="center" char="&#x000b1;">
<bold>water
(PDI)</bold>
<xref rid="t1fn2" ref-type="table-fn"/>
</th><th align="center" char="&#x000b1;">
<bold>PBS
(PDI)</bold>
<xref rid="t1fn2" ref-type="table-fn"/>
</th><th align="center" char="&#x000b1;">
<bold>&#x003b6;-potential
(mv)</bold>
<xref rid="t1fn3" ref-type="table-fn"/>
</th><th align="center" char=".">
<bold>
<italic toggle="yes">S</italic>
</bold>
<sub>
<bold>BET</bold>
</sub>
<bold>(m<sup>2</sup>/g)</bold>
<xref rid="t1fn4" ref-type="table-fn"/>
</th><th align="center" char=".">
<bold>
<italic toggle="yes">D</italic>
</bold>
<sub>
<bold>BJH</bold>
</sub>
<bold>(nm)</bold>
<xref rid="t1fn5" ref-type="table-fn"/>
</th></tr></thead><tbody><tr><td align="left">w-MSN@PEG/TA</td><td align="char" char="&#x000b1;">24.67 &#x000b1; 1.43</td><td align="char" char="&#x000b1;">38.3 &#x000b1; 0.77 (0.15)</td><td align="char" char="&#x000b1;">39.0 &#x000b1; 0.71 (0.14)</td><td align="char" char="&#x000b1;">9.1 &#x000b1; 1.08</td><td align="char" char=".">364.5</td><td align="char" char=".">2.4</td></tr><tr><td align="left">s-MSN@PEG/TA</td><td align="char" char="&#x000b1;">25.13 &#x000b1; 2.18</td><td align="char" char="&#x000b1;">43.0 &#x000b1; 0.06 (0.13)</td><td align="char" char="&#x000b1;">37.6 &#x000b1; 0.15 (0.01)</td><td align="char" char="&#x000b1;">18.1 &#x000b1; 1.10</td><td align="char" char=".">362.9</td><td align="char" char=".">2.3</td></tr><tr><td align="left">w-MSN@PEG/PEI</td><td align="char" char="&#x000b1;">26.09 &#x000b1; 1.70</td><td align="char" char="&#x000b1;">42.2 &#x000b1; 0.34 (0.20)</td><td align="char" char="&#x000b1;">42.7 &#x000b1; 0.49 (0.20)</td><td align="char" char="&#x000b1;">13.6 &#x000b1; 1.70</td><td align="char" char=".">242.5</td><td align="char" char=".">2.2</td></tr><tr><td align="left">s-MSN@PEG/PEI</td><td align="char" char="&#x000b1;">24.05 &#x000b1; 4.42</td><td align="char" char="&#x000b1;">43.5 &#x000b1; 0.32 (0.17)</td><td align="char" char="&#x000b1;">43.9 &#x000b1; 0.12 (0.19)</td><td align="char" char="&#x000b1;">19.1 &#x000b1; 0.75</td><td align="char" char=".">398.6</td><td align="char" char=".">2.1</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Measured by DLS.</p></fn><fn id="t1fn2"><label>b</label><p>Polydispersity index.</p></fn><fn id="t1fn3"><label>c</label><p>Measured by a zeta potential analyzer.</p></fn><fn id="t1fn4"><label>d</label><p>
<italic toggle="yes">S</italic>
<sub>BET</sub>: surface
area calculated from data using the BET equation.</p></fn><fn id="t1fn5"><label>e</label><p>
<italic toggle="yes">D</italic>
<sub>BJH</sub>: pore diameter
assigned from the maximum on the BJH pore size distribution.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3.2"><label>3.2</label><title>Assessment of the BBB Integrity
in the Brain
of Chick CAM</title><p>To evaluate the ability of various MSNs to cross
the BBB, subsequent experiments were conducted using the chick CAM
model. The experimental design, illustrated in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>a, outlines the timeline and procedure for
establishing the chick CAM model, as detailed in the experimental
section. For qualitative analysis, brain imaging and histological
staining of tissue sections will be used to visually assess the distribution
of MSNs and Dox. Quantitative analysis will involve tissue homogenization
followed by data quantification, providing precise measurements of
the distribution and concentration of MSNs and Dox in various tissues,
thereby offering a comprehensive understanding of their in vivo biodistribution.</p><fig position="float" id="fig2" fig-type="figure"><label>2</label><caption><p>Trypan
blue staining of BBB in the brain of chick CAM. (a) Schematic
illustration of the chick CAM model used for BBB studies. (b) Analysis
of BBB maturation on embryonic day 13 (embryonic immature) and 16
(embryonic mature) using trypan blue staining. (c) Photograph and
(d) fluorescence images (shown in red). Images depicting trypan blue
staining in chick CAM brains and major organs on embryonic day 16,
following injection on embryonic day 15. Scale bar: 100 nm.</p></caption><graphic xlink:href="am5c05429_0002" id="gr3" position="float"/></fig><p>To assess BBB integrity in chick brains, fertilized
eggs were preincubated
for either 12 days (representing embryonic immaturity) or 15 days
(representing embryonic maturity). A small window, approximately 1
cm in diameter, was cut into the eggshell for intravenous injection
of NPs. At 24 h postinjection (embryonic day 13 or 16), the chick
embryos were humanely sacrificed, and major organs were excised for
both quantitative and qualitative analyses. Evidence from MRI observations
strongly suggests that the structural development of the chick embryo
brain reaches full maturity after embryonic day 13.<xref rid="ref27" ref-type="bibr"/> To assess the integrity of the BBB at different stages
of chick CAM maturation, trypan blue dye was used as a marker to validate
BBB permeability. Trypan blue, due to its hydrophilicity (from sulfonic
acid groups) and large molecular size (MW = 960.8 g/mol, 1150 Da),
has limited capability to pass through a fully developed and intact
BBB.<named-content content-type="bibref-group">
<xref rid="ref37" ref-type="bibr"/>,<xref rid="ref38" ref-type="bibr"/>
</named-content> When the BBB is not fully developed, trypan
blue can leak from the bloodstream into brain tissue, resulting in
visible brain staining.<named-content content-type="bibref-group">
<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>
</named-content> This phenomenon serves
as an indicator of BBB integrity. In this study, BBB integrity in
the chick CAM was assessed by intravenous injection of trypan blue
(0.4%) on embryonic days 12 (embryonic immature) and 15 (embryonic
mature). The brains were excised 1 day postinjection for examination.
Photographs in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>b revealed noticeable trypan blue staining on embryonic day 13, whereas
brain samples from embryonic day 16 showed no staining, confirming
that the BBB was fully developed in the chick embryo by embryonic
day 15.</p><p>To further examine trypan blue-specific permeability
in major organs
(including the heart, liver, spleen, lungs, and kidneys) relative
to the brain, these organs were excised from trypan blue-injected
day 16 chick CAM embryos and imaged. <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>c demonstrated that trypan blue staining
was evident in all organs except for the brain and the control CAM,
indicating that trypan blue could not traverse the BBB to stain the
brain tissue. Subsequently, the collected organs were processed for
frozen tissue sectioning and imaged under a fluorescence microscope
to capture the red fluorescence signal of trypan blue (&#x003bb;ex:
633 nm). <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>d
showed that there was no red fluorescence signal in the control group
organs. In contrast, the trypan blue-injected chick CAM organs exhibited
a robust red fluorescence signal in major organs but notably absent
in the brain, consistent with the results shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>c. The inability of trypan
blue to penetrate brain tissue highlights the potential of the chick
CAM model as a valuable model for studying BBB integrity and permeability.</p></sec><sec id="sec3.3"><label>3.3</label><title>RMSN@PEG/TA Traverses the BBB without Causing
Disruption and Facilitates Penetration in the Live Chick CAM</title><p>To track the NP distribution and cellular internalization in vitro
and in vivo, various RITC- conjugated MSNs (RMSNs) were prepared.
Cellular internalization of various RMSNs was assessed in U87 glial
cells treated with different concentrations (250&#x02013;1000 &#x003bc;g/mL)
for 24 h using flow cytometry analysis. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>a revealed a dose-dependent increase in cellular
uptake for s-RMSN@PEG/TA, with approximately 80% uptake at a concentration
of 1000 &#x003bc;g/mL. In contrast, w-RMSN@PEG/TA exhibited significantly
lower uptake, around 10%, even at higher concentrations. Both s-RMSN@PEG/PEI
and w-RMSN@PEG/PEI consistently demonstrated nearly 100% cellular
uptake across all concentrations tested. <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Figure S1</ext-link> showed fluorescence imaging of cellular uptake of RMSNs
at various concentrations, consistent with the results in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>a. To evaluate NP-induced
cytotoxicity, the U87 glial cell line was treated with varying NP
concentrations (20&#x02013;400 &#x003bc;g/mL) for 24 h, and cytotoxicity
was measured using the CCK-8 assay (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>b). The results showed no cytotoxicity in
the RMSN@PEG/TA-treated groups, whereas the w-RMSN@PEG/PEI-treated
groups exhibited significant cell death. Additionally, s-RMSN@PEG/PEI-treated
groups showed dose-dependent cytotoxicity, indicating that PEI molecules
induce more pronounced cytotoxic effects compared to TA molecules.</p><fig position="float" id="fig3" fig-type="figure"><label>3</label><caption><p>Evaluation
of various RMSNs on cellular internalization, cytotoxicity
in U87 cells, and their efficacy in crossing the BBB in the chick
CAM. U87 cells were treated with various MSNs at indicated concentrations.
(a) Cellular uptake assessed using flow cytometry. (b) Cytotoxicity
analyzed by the CCK-8 assay. The chick CAM received intravenous injection
of various RMSNs at a dose of 1 mg/egg on embryonic day 15 and were
sacrificed 24 h after treatment. (c) IVIS imaging of brain distribution.
(d) Radiant efficiency of RMSNs in chick embryonic brains. <italic toggle="yes">N</italic> = 10. (e) Quantitative analysis of Si content in chick
brains using ICP-MS. (f) BBB integrity analysis of chick CAM 24 h
after treatment with RMSN@PEG/TA. (g) Biodistribution of RMSNs in
live embryonic chick brain. Schematic illustration of the chick calvarial
window model under a two-photon microscope. 3D reconstructed images
from two-photon microscopy showing RMSN@PEG/TA (red) and FITC-dextran
(green) distribution. (h) Confocal microscopy images of brain sections
with RMSN@PEG/TA (red) and DAPI-stained nuclei (blue). Scale bar:
20 &#x003bc;m. Data are presented as mean &#x000b1; SD. Statistical significance
was analyzed using Student&#x02019;s <italic toggle="yes">t</italic> test (*<italic toggle="yes">p</italic> &#x0003c; 0.05, **<italic toggle="yes">p</italic> &#x0003c; 0.01, ***<italic toggle="yes">p</italic> &#x0003c; 0.001, ****<italic toggle="yes">p</italic> &#x0003c; 0.0001).</p></caption><graphic xlink:href="am5c05429_0003" id="gr4" position="float"/></fig><p>Next, we explored the in vivo penetration efficiency
of various
RMSNs across the BBB. Chick CAM models with intact BBB at embryonic
day 15 were randomly assigned to five groups (control, s-RMSN@PEG/PEI,
w-RMSN@PEG/PEI, w-RMSN@PEG/TA, and s-RMSN@PEG/TA; N = 10 per group)
and then intravenously injected with different RMSNs (1 mg/egg). Brains
were harvested 24 h post-treatment, and RMSNs distribution was visualized
using the IVIS system by capturing the RITC signal (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>c). The RMSN@PEG/TA-treated
groups exhibited significantly stronger fluorescence intensity signals
compared to the control (nontreated) and RMSN@PEG/PEI-treated groups
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>d). Notably,
the RMSN@PEG/PEI-treated groups showed almost no fluorescence intensities,
indicating limited BBB penetration. These findings clearly indicated
that RMSN@PEG/TA effectively crosses the BBB, while RMSN@PEG/PEI did
not, suggesting the importance of surface properties in determining
the ability of RMSNs to traverse the BBB. Despite both types of RMSNs
possessing positive surface charges, the PEG/TA surface conferred
superior BBB penetration compared to the PEG/PEI surface.</p><p>Given
the higher IVIS fluorescence intensity observed for s-RMSN@PEG/TA
relative to w-RMSN@PEG/TA, we further assessed the silicon content
in the brain using ICP-MS analysis to quantify the efficiency of RMSNs
crossing the BBB. As shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>e, the silicon content in the s-RMSN@PEG/TA-treated
groups was nearly 1.6 times greater than that in the w-RMSN@PEG/TA-treated
groups. To evaluate the structural integrity of the chick CAM BBB
following RMSN@PEG/TA treatment, trypan blue staining was performed
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>f). The absence
of visible trypan blue staining suggested that RMSN@PEG/TA successfully
traversed the BBB without causing disruption. These results indicate
that the positively charged TA functionalization of RMSNs enhances
BBB penetration without compromising BBB integrity. The study proposes
that increased positive surface charge facilitates BBB penetration
of RMSN@PEG/TA. However, the biological pathways enabling RMSN@PEG/TA
to cross the BBB remain unclear and do not appear to involve direct
BBB disruption. Further research is needed to elucidate the underlying
mechanisms.</p><p>To gain more insight into the ability of RMSN@PEG/TA
to cross the
BBB, high-resolution imaging was conducted using a two-photon microscope
in the chick calvarial window model, as depicted in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>g. On embryonic day 15, after
intravenous injection of RMSN@PEG/TA (1 mg/egg), a calvarial window
was created in the chick CAM to access the brain 24 h post-treatment.
FITC-dextran (2.5 mg/mL), used to stain blood vessels, was injected
into the live chick CAM, and brain images were captured using the
two-photon microscope. The results showed that RMSN@PEG/TA (red, RITC)
was able to leak from blood vessels (green, FITC-dextran). This observation
clearly demonstrates that RMSN@PEG/TA is capable of crossing the BBB
in the live state of chick CAM brains. Owing to its significant and
higher distribution, s-RMSN@PEG/TA exhibited greater efficacy in crossing
the BBB compared to w-RMSN@PEG/TA, consistent with previous observations
in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>d and <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>e.</p><p>To further
confirm the distribution of NPs within the chick CAM
brain, frozen brain tissue sections were prepared and imaged with
RMSN@PEG/TA (red, RITC), and nuclei (blue, DAPI) using a confocal
microscope (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>h). The images demonstrated that both s-RMSN@PEG/TA and w-RMSN@PEG/TA
could penetrate the BBB and were subsequently internalized by cells
in the chick CAM brain. <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Figure S2</ext-link> presented
3D reconstructed confocal microscopy images of brain sections. The
above results suggest that MSNs with a stronger positive charge are
more effective in enhancing BBB penetration than those with a weaker
positive charge counterpart.</p></sec><sec id="sec3.4"><label>3.4</label><title>MSN@PEG/TA Promotes the
Delivery of Dox into
U87 Cells with Slow Release and Enhances Dox Transport Across the
BBB in the Chick CAM</title><p>NP-based drug delivery has emerged as
a promising therapeutic approach. In this study, the small molecule
drug doxorubicin (Dox), known for its intrinsic red fluorescence,
was chosen for investigation. The loading strategy is based on the
electrostatic interactions between the positively charged Dox and
negatively charged NPs. The loading efficacy and the amount of Dox
in w-MSN@PEG/TA were approximately 69% and 4.7%, respectively, whereas
those in s-MSN@PEG/TA were about 22% and 1.6%, respectively (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>a). <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>b illustrates the release profiles
of Dox and Dox-loaded MSNs under physiological (pH 7.4) and acidic
(pH 5.5) conditions. Both w-MSN@PEG/TA and s-MSN@PEG/TA exhibited
a slow cumulative release at both pH levels compared to Dox alone.
Notably, at equivalent Dox concentrations, the release rate of Dox
from w-MSN@PEG/TA and s-MSN@PEG/TA was faster at pH 5.5 than at pH
7.4, indicating pH-responsive release behavior. Importantly, w-MSN@PEG/TA
demonstrated superior drug release at pH 5.5 compared to s-MSN@PEG/TA,
which showed the slowest cumulative release at both pH levels.</p><fig position="float" id="fig4" fig-type="figure"><label>4</label><caption><p>In vitro Dox
loading, release, and cytotoxicity in U87 Cells treated
with Dox-loaded MSNs and transport of Dox across the BBB in the chick
CAM. (a) Loading efficiency and loading amount of Dox-loaded MSNs.
(b) Cumulative release profile of Dox from MSMs at pH 7.4 and 5.5.
(c) Cytotoxicity analysis of U87 cells treated with Dox alone, MSNs
(at equivalent Dox-loaded MSN concentration), and Dox-loaded MSNs
(at equivalent Dox alone concentration) across various concentrations
(1&#x02013;20 &#x003bc;g/mL). Cell viability was measured using a CCK-8
assay 24 h after treatment. (d) Western blot analysis showing protein
expression levels of Phospho-p38 and HMGB1. &#x003b1;-Tubulin was used
as a loading control. (e) IVIS imaging of Dox distribution. (f) Radiant
efficiency of Dox in chick embryonic brains. <italic toggle="yes">N</italic> =
10. (g) Quantitative analysis of Dox distribution in brain sections
using TissueQuest software. Quantitative analysis of tissue staining
and identification of nucleus-positive events were performed using
TissueFAXS and TissueQuest software platforms, respectively (red:
Dox; blue: DAPI-stained nuclei). (h) Confocal microscopy images of
brain sections showing Dox distribution (red) and nuclei (blue, DAPI
staining). Scale bar: 20 &#x003bc;m. (i) Drug permeability assay. Quantification
of Dox content in brain homogenates using fluorescence spectrophotometry.
Data are presented as mean &#x000b1; SD. Statistical significance was
analyzed using Student&#x02019;s <italic toggle="yes">t</italic> test (*<italic toggle="yes">p</italic> &#x0003c; 0.05, **<italic toggle="yes">p</italic> &#x0003c; 0.01, ***<italic toggle="yes">p</italic> &#x0003c; 0.001, ****<italic toggle="yes">p</italic> &#x0003c; 0.0001).</p></caption><graphic xlink:href="am5c05429_0004" id="gr5" position="float"/></fig><p>After 24 h of treatment, in vitro cytotoxicity
assays in U87 cells
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>c) revealed
that Dox alone and Dox-loaded MSNs (at concentrations equivalent to
Dox alone) induced dose-dependent cell death. MSNs without Dox loading
(at concentrations equivalent to those of Dox-loaded MSNs) exhibited
no cytotoxicity. Additionally, at treatment concentrations of 5 &#x003bc;g/mL
and higher, the toxicity of Dox@w-MSN@PEG/TA was similar to that of
Dox alone, whereas Dox@s-MSN@PEG/TA showed significantly lower toxicity
than Dox alone. To explore the molecular mechanisms underlying these
effects, Western blot analysis was conducted to detect the expression
levels of Phospho-p38 (an indicator of Dox-induced free radicals)
and HMGB1 (a protein associated with cell apoptosis), confirming that
cell death was due to Dox-induced cytotoxicity.<named-content content-type="bibref-group">
<xref rid="ref41" ref-type="bibr"/>,<xref rid="ref42" ref-type="bibr"/>
</named-content> As shown in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>d, the Dox-containing groups (Dox, Dox@w-MSN@PEG/TA, and Dox@s-MSN@PEG/TA)
exhibited higher expression levels of Phospho-p38 and HMGB1 than the
control and MSNs-treated groups without Dox loading, confirming the
effective delivery of Dox and subsequent induction of cell death.</p><p>Next, Dox delivery to the brain was investigated using MSN@PEG/TA
in the chick CAM. <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>e illustrates the brain images, where chick CAM was incubated
for 15 days, followed by intravenous injection of either Dox alone
(0.03 mg/egg), Dox@w-MSN@PEG/TA (at a Dox-equivalent concentration),
or Dox@s-MSN@PEG/TA (at a Dox-equivalent concentration). At 24 h postinjection,
chick embryo brains were dissected, and red fluorescent signals from
Dox (Ex: 480 nm, Em: 590 nm) were analyzed using an IVIS imaging system.
As expected, the control and Dox-alone groups showed no signal due
to the BBB restrictions, while the Dox@w-MSN@PEG/TA and Dox@s-MSN@PEG/TA-treated
groups exhibited significant Dox fluorescence. These results indicated
that MSNs effectively facilitated the transport of Dox across the
BBB. Quantitative IVIS analysis in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>f revealed a higher red fluorescence intensity
in the Dox@w-MSN@PEG/TA-treated groups, possibly due to its superior
Dox loading capacity compared to Dox@s-MSN@PEG/TA.</p><p>To further
confirm the transport and release of Dox via MSNs, frozen
brain tissue sections were prepared, and analyzed. Quantitative fluorescence
analysis was conducted using Tissue Quest to assess the fluorescence
intensity of Dox relative to DAPI staining (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>g). Results indicated that Dox was transported
more efficiently across the BBB in the Dox@s-MSN@PEG/TA-treated groups
compared to the Dox@w-MSN@PEG/TA-treated groups. Subsequently, the
Dox distribution was observed under a confocal microscope (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>h). Numerous red
spots were observed in the Dox@w-MSN@PEG/TA- and Dox@s-MSN@PEG/TA-treated
groups, suggesting successful Dox transport across the BBB. Nuclear
localization was confirmed using DAPI staining (shown in blue), and
the overlay of the Dox signal (shown in red) with blue nuclear staining
confirmed the intracellular distribution of Dox, providing evidence
of effective drug release within the cells. To quantify the Dox content
in the brain and compare drug penetration efficiencies between the
Dox@w-MSN@PEG/TA- and Dox@s-MSN@PEG/TA-treated groups, brain homogenates
were analyzed using spectrofluorometry. As shown in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>i, the drug permeability rate
of w-MSN@PEG/TA was approximately 0.25%, whereas that of s-MSN@PEG/TA
was approximately 0.75%, which is three times higher than that of
w-MSN@PEG/TA. The consistent results between <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>g and <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>i suggest that Dox is more effectively transported
across the BBB when using s-MSN@PEG/TA than when using w-MSN@PEG/TA.
Although s-MSN@PEG/TA had a lower Dox loading capacity than w-MSN@PEG/TA,
its superior transport and cellular uptake efficiency facilitated
more efficient BBB crossing and significantly enhanced drug delivery
into cells. Given that the mechanism of action of Dox involves entry
into the nucleus to induce cell death, these results support the successful
development of MSNs capable of efficiently carrying drugs across the
BBB and enabling drug release at the desired cellular targets.</p></sec><sec id="sec3.5"><label>3.5</label><title>Impact of Long PEG Chains on TA Molecules:
Steric Hindrance and Reduced BBB Penetration Efficiency</title><p>Long-chain
PEG coatings are known to shield NP surface ligands or molecules through
steric hindrance, potentially hindering their interaction with BBB
receptors or transporters and thereby impeding effective BBB penetration.<xref rid="ref17" ref-type="bibr"/> To investigate the role of TA molecules on MSNs
and their influence on BBB penetration, we replaced the shorter PEG-silane
(M.W. 459&#x02013;591) used in MSN@PEG/TA with long-chain PEG-silane
(M.W. One k, designated as PEG<sub>(L)</sub>-silane). Through this
modification, w-MSN@PEG<sub>(L)</sub>/TA and s-MSN@PEG<sub>(L)</sub>/TA were synthesized and their ability to penetrate the BBB was compared
with that of MSN@PEG/TA using both the chick CAM and mouse models
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>a). As shown
in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>b, TEM images
reveal that MSN@PEG<sub>(L)</sub>/TA possesses a uniform morphology
and a well-defined mesoporous structure. DLS analysis indicated that
the average particle sizes of MSN@PEG<sub>(L)</sub>/TA in water and
PBS, ranging from 46 to 54 nm, were larger than those of MSN@PEG/TA,
demonstrating the impact of the longer PEG chains on overall particle
size (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>c and <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). BET pore size analysis
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>d and <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) showed that the
pore sizes of w-MSN@PEG<sub>(L)</sub>/TA and s-MSN@PEG<sub>(L)</sub>/TA were comparable to those of MSN@PEG/TA, suggesting that the long-chain
PEG modification did not interfere with the TA surface modification.
X-ray diffraction (XRD) patterns exhibited a broad (100) peak, suggesting
short-range ordering in the structure of the MSNs (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>e).<xref rid="ref43" ref-type="bibr"/> The XRD patterns of MSN@PEG/TA and MSN@PEG<sub>(L)</sub>/TA displayed
typical diffraction peaks at 2&#x003b8; values of 2.142&#x000b0;, corresponding
to the hexagonal mesoporous silica structure similar to bare MSNs.
This indicates that the surface modification did not compromise the
structural integrity of the MSNs. As shown in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Figure S5</ext-link>, all MSNs exhibited Si&#x02013;OH (950 cm<sup>&#x02013;1</sup>) and Si&#x02013;O&#x02013;Si (1000&#x02013;1200 cm<sup>&#x02013;1</sup>) stretching bands, indicating well-preserved silica frameworks.
A distinct C&#x02013;H stretching band near 2880 cm<sup>&#x02013;1</sup>confirmed the successful attachment of PEG in all PEG-modified MSNs,
while enhanced absorption in the 1550&#x02013;1650 cm<sup>&#x02013;1</sup>range in all TA-modified MSNs indicated the incorporation of quaternary
ammonium groups. Overall, these FTIR results clearly confirm the effective
dual functionalization of MSNs with both PEG- and TA-silane. TGA profiles
showed three distinct weight loss stages: the first stage (below 40
&#x000b0;C&#x02013;200 &#x000b0;C) corresponded to the evaporation of physically
adsorbed water; the second stage (200 &#x000b0;C&#x02013;600 &#x000b0;C)
was attributed to the decomposition of PEG/TA; and the final stage
(600 &#x000b0;C&#x02013;800 &#x000b0;C) represented further degradation of
PEG/TA. As shown in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>f and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Table S2</ext-link>, the weight loss
(200 &#x000b0;C&#x02013;600 &#x000b0;C) for w-MSN@PEG/TA and s-MSN@PEG/TA
was 27.4% and 21.1%, respectively, after accounting for the baseline
weight loss of bare MSN (6.5%). In contrast, the weight loss for w-MSN@PEG<sub>(L)</sub>/TA and s-MSN@PEG<sub>(L)</sub>/TA was 8.7% and 10.9%, respectively.
This reduced weight loss for MSN@PEG<sub>(L)</sub>/TA compared to
MSN@PEG/TA can be attributed to the steric hindrance of the long-chain
PEG-silane, which limits the accessibility of PEG<sub>(L)</sub>/TA
molecules for conjugation.</p><fig position="float" id="fig5" fig-type="figure"><label>5</label><caption><p>Impact of long-chain PEG on RMSNs for BBB penetration.
(a) Schematic
illustration of MSN@PEG<sub>(L)</sub>/TA for BBB studies. (b) TEM
images and size distribution histograms of MSN@PEG<sub>(L)</sub>/TA.
Scale bar: 100 nm. (c) DLS analysis showing the size distribution
of MSN@PEG<sub>(L)</sub>/TA in ddH<sub>2</sub>O and PBS. (d) Nitrogen
adsorption&#x02013;desorption isotherms and the corresponding pore
size distribution plot of MSN@PEG<sub>(L)</sub>/TA. (e) XRD patterns.
(f) TGA-derived weight loss percentages. (g) Zeta potential measurements.
(h) Cellular uptake of various RMSNs in U87 cells was assessed by
flow cytometry. (i) IVIS imaging and (j) radiant efficiency of RMSN@PEG<sub>(L)</sub>/TA in chick embryonic brains 24 h post-treatment following
intravenous injection (1 mg/egg) on embryonic day 15. <italic toggle="yes">N</italic> = 8. (k) IVIS imaging and (l) radiant efficiency of various RMSNs
injected intravenously at 200 mg/kg body weight in mouse brains. <italic toggle="yes">N</italic> = 5. Data are presented as mean &#x000b1; SD. Statistical
significance was analyzed using Student&#x02019;s <italic toggle="yes">t</italic> test (*<italic toggle="yes">p</italic> &#x0003c; 0.05, **<italic toggle="yes">p</italic> &#x0003c; 0.01,
***<italic toggle="yes">p</italic> &#x0003c; 0.001, ****<italic toggle="yes">p</italic> &#x0003c; 0.0001).</p></caption><graphic xlink:href="am5c05429_0005" id="gr6" position="float"/></fig><table-wrap position="float" id="tbl2"><label>2</label><caption><title>Basic Characterization of MSN@PEG<sub>(L)</sub>/TA</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th align="center">&#x000a0;</th><th align="center" char="&#x000b1;">&#x000a0;</th><th colspan="2" align="center" char="&#x000b1;">
<bold>size (nm)</bold>
<xref rid="t2fn1" ref-type="table-fn"/>
<hr/></th><th align="center" char="&#x000b1;">&#x000a0;</th><th align="center" char=".">&#x000a0;</th><th align="center" char=".">&#x000a0;</th></tr><tr><th align="center">
<bold>sample</bold>
</th><th align="center" char="&#x000b1;">
<bold>average
size from TEM (nm)</bold>
</th><th align="center" char="&#x000b1;">
<bold>water
(PDI)</bold>
<xref rid="t2fn2" ref-type="table-fn"/>
</th><th align="center" char="&#x000b1;">
<bold>PBS
(PDI)</bold>
<xref rid="t2fn2" ref-type="table-fn"/>
</th><th align="center" char="&#x000b1;">
<bold>&#x003b6;-potential
(mv)</bold>
<xref rid="t2fn3" ref-type="table-fn"/>
</th><th align="center" char=".">
<bold>
<italic toggle="yes">S</italic>
</bold>
<sub>
<bold>BET</bold>
</sub>
<bold>(m<sup>2</sup>/g)</bold>
<xref rid="t2fn4" ref-type="table-fn"/>
</th><th align="center" char=".">
<bold>
<italic toggle="yes">D</italic>
</bold>
<sub>
<bold>BJH</bold>
</sub>
<bold>(nm)</bold>
<xref rid="t2fn5" ref-type="table-fn"/>
</th></tr></thead><tbody><tr><td align="left">w-MSN@PEG<sub>(L)</sub>/TA</td><td align="char" char="&#x000b1;">25.84
&#x000b1; 2.96</td><td align="char" char="&#x000b1;">48.0
&#x000b1; 0.38 (0.27)</td><td align="char" char="&#x000b1;">46.6 &#x000b1; 0.46 (0.25)</td><td align="char" char="&#x000b1;">7.9 &#x000b1; 0.41</td><td align="char" char=".">91.8</td><td align="char" char=".">2.1</td></tr><tr><td align="left">s-MSN@PEG<sub>(L)</sub>/TA</td><td align="char" char="&#x000b1;">28.22
&#x000b1; 3.11</td><td align="char" char="&#x000b1;">53.3
&#x000b1; 0.42 (0.39)</td><td align="char" char="&#x000b1;">49.0 &#x000b1; 0.39 (0.38)</td><td align="char" char="&#x000b1;">18.0 &#x000b1; 2.47</td><td align="char" char=".">210.2</td><td align="char" char=".">2.2</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Measured by DLS.</p></fn><fn id="t2fn2"><label>b</label><p>Polydispersity index.</p></fn><fn id="t2fn3"><label>c</label><p>Measured by a zeta potential analyzer.</p></fn><fn id="t2fn4"><label>d</label><p>
<italic toggle="yes">S</italic>
<sub>BET</sub>: surface
area calculated from data using the BET equation.</p></fn><fn id="t2fn5"><label>e</label><p>
<italic toggle="yes">D</italic>
<sub>BJH</sub>: pore diameter
assigned from the maximum on the BJH pore size distribution.</p></fn></table-wrap-foot></table-wrap><p>Surface charge measurements revealed
that w-MSN@PEG<sub>(L)</sub>/TA and s-MSN@PEG<sub>(L)</sub>/TA had
zeta potentials of 7.9 &#x000b1;
0.41 mV and 18.0 &#x000b1; 2.47 mV, respectively, which are similar to
the zeta potentials of w-MSN@PEG/TA (9.1 &#x000b1; 1.08 mV) and s-MSN@PEG/TA
(18.1 &#x000b1; 1.10 mV) (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>g and <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). Elemental Analysis confirmed the successful conjugation of long-chain
PEG onto MSNs, as indicated by detectable carbon content (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Table S1</ext-link>). Notably, s-MSN@PEG<sub>(L)</sub>/TA
exhibited a higher degree of TA modification, as evidenced by increased
nitrogen content compared to w-MSN@PEG<sub>(L)</sub>/TA, resulting
in a higher strong positive charge. Overall, the successful preparation
of MSN@PEG<sub>(L)</sub>/TA was validated by increased particle size,
detectable carbon content, and weight loss patterns. While the surface
charge trends of MSN@PEG/TA and MSN@PEG<sub>(L)</sub>/TA were comparable,
the primary difference lay in the PEG chain length. Using data from
TEM, TGA, XRD, Elemental analysis, and BET pore size measurements,
we calculated the PEG density for MSN@PEG/TA and MSN@PEG<sub>(L)</sub>/TA (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link> for details).
Based on the surface area available for PEG modification per gram
(nm<sup>2</sup>/g) (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Table S3</ext-link>) and the number
of PEG molecules (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>), the PEG density for w-MSN@PEG/TA was approximately 3.52 chains/nm<sup>2</sup>, while that for s-MSN@PEG/TA was about 1.69 chains/nm<sup>2</sup>. Similarly, the PEG density for w-MSN@PEG<sub>(L)</sub>/TA
was 0.42 chains/nm<sup>2</sup>, while that for s-MSN@PEG<sub>(L)</sub>/TA was 0.12 chains/nm<sup>2</sup>. These results indicate significant
differences in PEG density among the four materials.</p><table-wrap position="float" id="tbl3" orientation="landscape"><label>3</label><caption><title>Comparison of PEG Grafting Density
on MSN@PEG/TA and MSN@PEG<sub>(L)</sub>/TA</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="&#x000d7;"/><col align="char" char="."/><col align="char" char="."/><col align="left"/><col align="char" char="&#x000d7;"/><col align="char" char="&#x000d7;"/><col align="char" char="&#x000d7;"/><col align="char" char="."/><col align="left"/></colgroup><thead><tr><th align="center">sample</th><th align="center" char=".">weight of
functionalized MSN<xref rid="t3fn1" ref-type="table-fn"/> (g)</th><th align="center" char="&#x000d7;">weight of
functional groups<xref rid="t3fn2" ref-type="table-fn"/> (g)</th><th align="center" char=".">nitrogen
percentage (<italic toggle="yes">N</italic> %) of TA<xref rid="t3fn3" ref-type="table-fn"/>
</th><th align="center" char=".">molecular
weight (M.W.) of TA<xref rid="t3fn4" ref-type="table-fn"/>
</th><th align="center">number of
nitrogen atoms in TA<xref rid="t3fn5" ref-type="table-fn"/>
</th><th align="center" char="&#x000d7;">weight of
TA<xref rid="t3fn6" ref-type="table-fn"/> (g)</th><th align="center" char="&#x000d7;">weight of
PEG<xref rid="t3fn7" ref-type="table-fn"/> (g)</th><th align="center" char="&#x000d7;">number of
PEG molecules<xref rid="t3fn8" ref-type="table-fn"/> (chains)</th><th align="center" char=".">PEG density<xref rid="t3fn9" ref-type="table-fn"/> (chains/nm<sup>2</sup>)</th><th align="center">PEG conformation<xref rid="t3fn10" ref-type="table-fn"/>
</th></tr></thead><tbody><tr><td align="left">w-MSN@PEG/TA</td><td align="char" char=".">1.377</td><td align="char" char="&#x000d7;">3.774 &#x000d7; 10<sup>&#x02013;1</sup>
</td><td align="char" char=".">0.386</td><td align="char" char=".">101.2</td><td align="left">1</td><td align="char" char="&#x000d7;">3.843 &#x000d7; 10<sup>&#x02013;2</sup>
</td><td align="char" char="&#x000d7;">3.390 &#x000d7; 10<sup>&#x02013;1</sup>
</td><td align="char" char="&#x000d7;">5.065
&#x000d7; 10<sup>20</sup>
</td><td align="char" char=".">3.52</td><td align="left">dense brush</td></tr><tr><td align="left">s-MSN@PEG/TA</td><td align="char" char=".">1.267</td><td align="char" char="&#x000d7;">2.674 &#x000d7; 10<sup>&#x02013;1</sup>
</td><td align="char" char=".">0.891</td><td align="char" char=".">101.2</td><td align="left">1</td><td align="char" char="&#x000d7;">8.162 &#x000d7;
10<sup>&#x02013;2</sup>
</td><td align="char" char="&#x000d7;">1.858 &#x000d7; 10<sup>&#x02013;1</sup>
</td><td align="char" char="&#x000d7;">2.777 &#x000d7; 10<sup>20</sup>
</td><td align="char" char=".">1.96</td><td align="left">dense brush</td></tr><tr><td align="left">w-MSN@PEG<sub>(L)</sub>/TA</td><td align="char" char=".">1.095</td><td align="char" char="&#x000d7;">0.953 &#x000d7; 10<sup>&#x02013;1</sup>
</td><td align="char" char=".">0.710</td><td align="char" char=".">101.2</td><td align="left">1</td><td align="char" char="&#x000d7;">5.621 &#x000d7; 10<sup>&#x02013;2</sup>
</td><td align="char" char="&#x000d7;">3.908 &#x000d7; 10<sup>&#x02013;2</sup>
</td><td align="char" char="&#x000d7;">5.840
&#x000d7; 10<sup>19</sup>
</td><td align="char" char=".">0.42</td><td align="left">brush</td></tr><tr><td align="left">s-MSN@PEG<sub>(L)</sub>/TA</td><td align="char" char=".">1.122</td><td align="char" char="&#x000d7;">1.223 &#x000d7; 10<sup>&#x02013;1</sup>
</td><td align="char" char=".">1.385</td><td align="char" char=".">101.2</td><td align="left">1</td><td align="char" char="&#x000d7;">11.24 &#x000d7; 10<sup>&#x02013;2</sup>
</td><td align="char" char="&#x000d7;">9.982 &#x000d7; 10<sup>&#x02013;3</sup>
</td><td align="char" char="&#x000d7;">1.492 &#x000d7; 10<sup>19</sup>
</td><td align="char" char=".">0.12</td><td align="left">mushroom-brush</td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p>Weight of functionalized
MSN <inline-formula>
<alternatives><graphic xlink:href="am5c05429_m004" position="float"/><mml:math id="d1e1721" display="inline"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>Z</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>TGA</mml:mi><mml:mspace width="0.25em"/><mml:mi>functional</mml:mi><mml:mspace width="0.25em"/><mml:mi>group</mml:mi><mml:mspace width="0.25em"/><mml:mi>weight</mml:mi><mml:mspace width="0.25em"/><mml:mi>percentage</mml:mi></mml:mrow></mml:mfrac><mml:mi mathvariant="script">g</mml:mi></mml:math></alternatives>
</inline-formula>
</p></fn><fn id="t3fn2"><label>b</label><p>Weight of functional groups = Z
&#x02013; 1 g.</p></fn><fn id="t3fn3"><label>c</label><p>Given from
the nitrogen percentage
(<italic toggle="yes">N</italic> %) obtained by elemental analysis (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Table S1</ext-link>).</p></fn><fn id="t3fn4"><label>d</label><p>Combustible M.W. of TA-saline: M.W.
= 257.83; Effective M.W. used for TGA calculation: M.W. = 101.2.</p></fn><fn id="t3fn5"><label>e</label><p>Based on the molecular structure
of TA (<italic toggle="yes">N</italic> = 1).</p></fn><fn id="t3fn6"><label>f</label><p>Weight of <inline-formula>
<alternatives><graphic xlink:href="am5c05429_m005" position="float"/><mml:math id="d1e1776" display="inline"><mml:mi>TA</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Z</mml:mi><mml:mo>&#x000d7;</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mo>%</mml:mo></mml:mrow><mml:mrow><mml:mn>14</mml:mn></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:msub><mml:mrow><mml:mi>TA</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mo>.</mml:mo><mml:mi>W</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:msub><mml:mi mathvariant="normal">g</mml:mi></mml:math></alternatives>
</inline-formula>
</p></fn><fn id="t3fn7"><label>g</label><p>Weight of PEG = (Z &#x02013; 1) &#x02013;
weight of TA g.</p></fn><fn id="t3fn8"><label>h</label><p>Number of <inline-formula>
<alternatives><graphic xlink:href="am5c05429_m006" position="float"/><mml:math id="d1e1814" display="inline"><mml:mi>PEG</mml:mi><mml:mspace width="0.25em"/><mml:mi>Molecules</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>Weight</mml:mi><mml:mspace width="0.25em"/><mml:mi>of</mml:mi><mml:mspace width="0.25em"/><mml:mi>PEG</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>PEG</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="normal">W</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>6.0221</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>23</mml:mn></mml:mrow></mml:msup></mml:math></alternatives>
</inline-formula> chains.</p></fn><fn id="t3fn9"><label>i</label><p>
<inline-formula>
<alternatives><graphic xlink:href="am5c05429_m007" position="float"/><mml:math id="d1e1852" display="inline"><mml:mi>PEG</mml:mi><mml:mspace width="0.25em"/><mml:mi>density</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>Number</mml:mi><mml:mspace width="0.25em"/><mml:mi>of</mml:mi><mml:mspace width="0.25em"/><mml:mi>PEG</mml:mi><mml:mspace width="0.25em"/><mml:mi>molecules</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">S</mml:mi><mml:mi>PEG</mml:mi></mml:msub><mml:mi>per</mml:mi><mml:mspace width="0.25em"/><mml:mi>gram</mml:mi></mml:mrow></mml:mfrac><mml:mi>chains</mml:mi><mml:mo>/</mml:mo><mml:msup><mml:mi>nm</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></alternatives>
</inline-formula>
</p></fn><fn id="t3fn10"><label>j</label><p>PEG conformation is referenced
in Reference <xref rid="ref36" ref-type="bibr" specific-use="ref-style=base-text"/>,
where it is categorized as follows: mushroom (&#x0003c;0.2 chains/nm<sup>2</sup>), brush (0.2&#x02013;0.5 chains/nm<sup>2</sup>), and dense
brush (&#x0003e;0.5 chains/nm<sup>2</sup>).</p></fn></table-wrap-foot></table-wrap><p>To evaluate the impact of long-chain PEG on cellular
internalization,
U87 glial cells were exposed to varying concentrations of RITC-conjugated
MSN@PEG<sub>(L)</sub>/TA (RMSN@PEG<sub>(L)</sub>/TA, 20&#x02013;400
&#x003bc;g/mL), with no significant cytotoxicity observed (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Figure S3</ext-link>). Subsequently, U87 glial cells were
treated with various RMSN@PEG<sub>(L)</sub>/TA at a concentration
of 1000 &#x003bc;g/mL for 24 h, and cellular uptake was analyzed using
flow cytometry (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>h). As expected, no significant cellular uptake was observed in the
w-RMSN@PEG/TA and w-RMSN@PEG<sub>(L)</sub>/TA-treated groups. However,
the cellular uptake of s-RMSN@PEG<sub>(L)</sub>/TA (&#x0223c;40%) was
notably lower than that of s-RMSN@PEG/TA (&#x0223c;80%), confirming
that the long-chain PEG effectively shields TA molecules and reduces
cell internalization due to steric hindrance. Subsequently, we investigated
the in vivo penetration efficiency of RMSN@PEG<sub>(L)</sub>/TA across
the BBB. Chick CAM models with an intact BBB at embryonic day 15 were
randomly assigned to three experimental groups (N = 8): control, w-RMSN@PEG<sub>(L)</sub>/TA, and s-RMSN@PEG<sub>(L)</sub>/TA. Following intravenous
injection (1 mg/egg), the distribution of NPs in the brain was analyzed
24 h post-treatment using an IVIS imaging system. As shown in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>i, the RITC signals
were significantly reduced in both RMSN@PEG<sub>(L)</sub>/TA-treated
groups compared to the w-RMSN@PEG/TA-treated groups (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>c), suggesting that the long-chain
PEG hinders BBB penetration. Additionally, the radiant efficiency
of fluorescence intensity indicated that s-RMSN@PEG<sub>(L)</sub>/TA
maintained a stronger signal than w-RMSN@PEG<sub>(L)</sub>/TA, likely
due to its enhanced positive charge, which contributed to superior
BBB penetration efficacy (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>j).</p><p>To verify the chick CAM results, a similar
experiment was conducted
in mice. Mice were intravenously injected with 200 mg/kg body weight
of various RMSNs, focusing on those with stronger positive charges.
After 24 h, the distribution of s-RMSN@PEG/PEI, s-RMSN@PEG/TA, and
s-RMSN@PEG<sub>(L)</sub>/TA in the brain was visualized using an IVIS
imaging system to capture the RITC fluorescence signals. As shown
in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>k, detectable
fluorescent signals were observed in the s-RMSN@PEG/TA and s-RMSN@PEG<sub>(L)</sub>/TA-treated groups, whereas the s-RMSN@PEG/PEI-treated groups
did not show any signal. Notably, the radiant efficiency of fluorescence
intensity in the s-RMSN@PEG/TA-treated groups was higher than in the
w-RMSN@PEG<sub>(L)</sub>/TA-treated groups (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>l), suggesting that the long-chain PEG effectively
shields TA molecules, reducing BBB penetration capability. The results
from the mouse model were consistent with those from the chick CAM
model, further demonstrating the potential of chick CAM as a viable
BBB model. These findings highlight the vital role of the positively
charged TA molecule in facilitating MSN transport across the BBB,
while also revealing the potential drawbacks of long-chain PEG, which
may hinder BBB penetration due to steric hindrance.</p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p>Functionalization of MSNs
with positively charged
molecules is
a strategic approach for enhancing drug delivery across the BBB. Tertiary
amines, particularly those in the branched cationic polymer polyethyleneimine
(PEI), are highly toxic to cells, posing a safety issue.<xref rid="ref44" ref-type="bibr"/> The positive charge of branched PEI can be conjugated
with NPs as carriers to enhance BBB penetration. However, concerns
arise due to the inherent high toxicity of tertiary amines, especially
when combined with high-molecular-weight PEI, leading to significant
disruption of cell membranes and cytotoxicity. To overcome this shortcoming,
surface modifications with PEGylation (attaching polyethylene glycol
chains) can both enhance NP stability in the bloodstream and mitigate
cytotoxicity.<xref rid="ref45" ref-type="bibr"/> However, achieving a critical
balance in optimizing the density and ratio of PEG and PEI on NPs
is challenging but crucial for enhancing BBB penetration without compromising
safety. Additionally, protein corona (PC) formation, in which serum
proteins adsorb onto the NP surface, and buffering capacity can impact
the cellular uptake of PEI-NPs, thus affecting NPs biodistribution
and BBB penetration.<xref rid="ref46" ref-type="bibr"/>
</p><p>Alternatively,
the quaternization of primary amines to form quaternary
ammonium groups has been proposed as a strategy to mitigate toxicity
while maintaining the overall positive charge of NPs.<xref rid="ref47" ref-type="bibr"/> This method produces desirable positively charged NPs that
interact favorably with negatively charged cell membranes, thereby
facilitating BBB penetration. Our recent findings have proven the
potential of MSNs functionalized with a positively charged quaternary
ammonium molecule, trimethylammonium (TA), to facilitate BBB penetration
in mice.<xref rid="ref48" ref-type="bibr"/> To further explore the impact
of positive charge on BBB crossing, this study delves into the differences
in BBB crossing between two types of PEGylated positively charged
MSNs (MSN@PEG/PEI and MSN@PEG/TA), each with varying degrees of positive
charge, including strong and weak charges. We demonstrated that the
quaternary ammonium molecule of TA represents a promising approach,
which not only mitigates cytotoxicity but also enhances BBB penetration
when functionalized onto RMSNs. In contrast, tertiary amines of branched
PEI exhibit significant cytotoxicity and are ineffective at crossing
the BBB (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>b
and <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>c). Although
the specific mechanisms associated with BBB penetration by RMSN@PEG/TA
remain unclear, we found that its penetration does not involve BBB
disruption (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>f). Considering its small size (25 nm) and positive charge, we propose
that MSN@PEG/TA may facilitate BBB penetration via diffusion and adsorption-mediated
transcytosis mechanisms. To clarify the possible mechanisms, further
detailed studies need to be conducted.</p><p>As shown in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Table S1</ext-link>, element analysis
results demonstrated that s-MSN@PEG/TA has a higher TA modification
quantity, resulting in enhanced positive charge surface properties.
BET pore size analysis (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>e and <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>) indicates that the pore size of s-MSN@PEG/TA is smaller than w-MSN@PEG/TA,
suggesting that the increased TA modification leads to a reduction
in pore size, causing lower drug loading. (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>a) Additionally, we employed the positive&#x02013;negative
electrostatic attraction method for drug loading on MSNs. Dox adsorption
was facilitated by changing the charge properties through an alkaline
solution. Following alkaline treatment at pH 10.0, the surface charge
of s-MSN@PEG/TA becomes weakly negative value (&#x02212;8 mv), while
w-MSN@PEG/TA has a stronger negatively charged surface (&#x02212;17
mv) (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Figure S4</ext-link>). Hence, w-MSN@PEG/TA makes
it easy for positively charged Dox to adsorb on the MSN surface or
pores, whereas the charge properties of s-MSN@PEG/TA make it less
favorable for Dox adsorption. Consequently, the drug loading of w-MSN@PEG/TA
is higher than that of s-MSN@PEG/TA (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>a). The MSN itself possesses the property
of slow drug release. When comparing w-MSN@PEG/TA and s-MSN@PEG/TA,
the latter exhibits a slower drug release profile, likely due to its
denser TA grafting and smaller pore size, which creates a barrier
that impedes drug release (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>b). The cytotoxicity result in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>C was consistent with the drug release results.
The slow drug release rate of Dox@s-MSN@PEG/TA leads to lower toxicity
compared to Dox@w-MSN@PEG/TA. Additionally, the surface charge of
w-MSN@PEG/TA was higher than that of s-MSN@PEG/TA when the MSNs were
in either the physiological pH 7.4 or lower pH 5.5 (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">Figure S4</ext-link>), which enhanced the Dox release due to the charge&#x02013;charge
repulsion.<named-content content-type="bibref-group">
<xref rid="ref49" ref-type="bibr"/>,<xref rid="ref50" ref-type="bibr"/>
</named-content> The cytotoxic induction capability
of Dox@w-MSN@PEG/TA is higher than Dox@s-MSN@PEG/TA, possibly due
to the faster Dox release rate in Dox@w-MSN@PEG/TA, resulting in a
higher cumulative release amount (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>b). In this study, cytotoxicity assays were
conducted using U87 glioma cells to evaluate the therapeutic relevance
of MSN@PEG/TA formulations. While these results provide valuable insights
into the efficacy of the nanoparticles, a more comprehensive safety
assessment requires further validation in noncancerous human cells.
Future studies should include cytotoxicity evaluations in normal cell
types, such as human umbilical vein endothelial cells (HUVECs), neuronal
stem cells, astrocytes, and potentially in vivo mouse models. Such
investigations will be critical for assessing biocompatibility, minimizing
off-target toxicity, and advancing the translational potential of
MSN-based drug delivery systems for CNS-related therapies.</p><p>Biomedical
research frequently relies on mice as a model organism
due to their physiological and genetic similarities to humans, which
have been estimated to be approximately 90%.<xref rid="ref51" ref-type="bibr"/> These characteristics provide a robust basis for utilizing mice
in the pursuit of biomedical research. However, the process of obtaining
results using mouse models can be expensive and time-consuming, particularly
given the slow progress in drug development for pathological brain
diseases.<xref rid="ref52" ref-type="bibr"/> In addition to mice, zebrafish
(Danio rerio) have gained popularity as model organisms, especially
for the study of developmental and dynamic processes.<xref rid="ref53" ref-type="bibr"/> Zebrafish offer advantages such as transparency, genetic
manipulability, a high reproductive rate, and the capability for high-throughput
screening, making it well suited for studying the BBB.<xref rid="ref54" ref-type="bibr"/> Despite these benefits, it is essential to acknowledge
discrepancies between zebrafish and mammals in terms of anatomy, physiology,
and the immune system. As a result, research conducted in zebrafish
models often necessitates validation using mouse models. Given these
considerations, there is an urgent need to develop an alternative
animal model that incorporates the advantages of both mice and zebrafish
to achieve highly reproducible results in BBB studies.</p><p>The chicken
chorioallantoic membrane (CAM) model is a valuable
and cost-effective model for conducting biological research, particularly
in the areas of angiogenesis, tumor growth, toxicity studies, and
drug testing.<named-content content-type="bibref-group">
<xref rid="ref35" ref-type="bibr"/>,<xref rid="ref36" ref-type="bibr"/>
</named-content> The CAM model offers a unique
balance between fundamental information and detailed research, serving
as a bridge between in vitro and in vivo studies.<xref rid="ref26" ref-type="bibr"/> The benefits of the CAM model<named-content content-type="bibref-group">
<xref rid="ref55" ref-type="bibr"/>&#x02212;<xref rid="ref56" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref57" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref58" ref-type="bibr"/>
</named-content> include (1) Accessibility: Fertilized
chicken eggs are readily available and affordable, making the CAM
model accessible to a wide range of researchers; (2) Transparency:
The CAM model allows for easy observation of extensive vascularization,
tumor growth, and other biological phenomena in real time; (3) In
vivo experiments: The model provides an in vivo environment, resulting
in observations that are more relevant to human biology compared to
in vitro models; (4) Short experimental duration: Rapid development
of the CAM model often shortens experimental times compared to other
mammalian animal models; (5) Natural immunodeficiency: In the early
stages of development, the CAM model lacks a well-developed immune
system, which is beneficial for the growth of implanted xenogeneic
tumor cells and the formation of vascular networks; (6) Ethical Advantages:
Given the absence of pain perception, the chick CAM model is not considered
a living animal until E17 (in most countries) or even until hatching.
Experiments involving chick CAM do not require ethical restrictions
or protocol approval from animal welfare or ethics committees, thus
simplifying the planning process. In this study, we have proven that
the chick CAM model provides a good BBB penetration evaluation platform
with comparable outcomes with the mouse model. With a lower cost in
comparison to mouse experiments and a closer in vivo environment when
compared to zebrafish, the chick CAM model could be an alternative
animal model for biomedical applications.</p><p>Evidence suggests
that the molecular weight (MW) and density of
PEG are critical factors influencing the physicochemical and biological
properties of NPs.<named-content content-type="bibref-group">
<xref rid="ref59" ref-type="bibr"/>&#x02212;<xref rid="ref60" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref61" ref-type="bibr"/>
</named-content> In this study, we focus on the impact of PEG chain
length on BBB penetration when conjugated onto the NP surface. PEGylation,
the process of conjugating PEG onto NPs, creates a hydrophilic and
flexible surface that enhances NP circulation in the bloodstream,
reduces clearance by the mononuclear phagocyte system (MPS), and minimizes
protein corona formation.<xref rid="ref62" ref-type="bibr"/> While PEGylation,
particularly with long-chain PEG, provides these benefits, it also
presents challenges, especially in terms of its effects on the biomolecular
function and behavior of NPs. The main issues include (1) Reduced
Cellular Uptake: the hydrophilic nature of long-chain PEG reduces
interactions between NPs and the largely hydrophobic cell membranes,
significantly decreasing cellular uptake. This limits the intracellular
delivery of therapeutic agents;<xref rid="ref61" ref-type="bibr"/> (2) Steric
Hindrance: excessively long PEG chains can create steric hindrance
around the NP surface, hindering the binding efficiency of targeted
ligands, such as antibodies or aptamers. This steric barrier of the
PEG layer may prevent these ligands from effectively interacting with
their targets, diminishing targeting efficiency.<named-content content-type="bibref-group">
<xref rid="ref63" ref-type="bibr"/>,<xref rid="ref64" ref-type="bibr"/>
</named-content> In our study, we observed that long-chain PEG effectively shields
TA molecules, leading to reduced cell internalization in U87 cells
(<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>d) and impaired
BBB penetration in vivo (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>e and <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>g) due to steric hindrance. This finding underscores the potential
impact of PEG chain length on the effectiveness of NPs in crossing
the BBB. We found that TA was the key element that facilitated the
BBB crossing of the MSNs.</p><p>Densely packed PEG chains can affect
the formation of the protein
corona and mask targeting ligands on the NP surface, particularly
when NPs are intended to cross the BBB.<xref rid="ref65" ref-type="bibr"/> The protein corona alters the behavior and fate of NPs and may also
obscure surface-bound targeting ligands. NPs coated with PEG in a
low-density mushroom configuration offer weak resistance to serum
protein adsorption due to the creation of a thinner hydrophobic barrier.<xref rid="ref66" ref-type="bibr"/> In contrast, a dense brush configuration of
PEG forms a thicker hydrophilic barrier that is more effective at
blocking protein adsorption.<xref rid="ref67" ref-type="bibr"/> Walkey et
al. reported that steric hindrance from the high grafting density
of PEG chains in the brush configuration could limit serum protein
binding.<xref rid="ref67" ref-type="bibr"/> However, even at high PEG density,
complete prevention of protein adsorption is not achievable, and excessive
PEGylation may also inhibit cellular uptake.<named-content content-type="bibref-group">
<xref rid="ref68" ref-type="bibr"/>,<xref rid="ref69" ref-type="bibr"/>
</named-content> Therefore, fine-tuning the MW and surface density of PEG, along
with the biophysical and chemical characteristics of NPs, is critical
for improving BBB penetration and optimizing drug delivery to the
brain. To address these challenges, it is essential to carefully design
the PEGylation process to balance stealth properties and functional
efficacy. A common strategy to reduce the shielding effect is to optimize
the length or density of PEG chains. In this study, we used short-PEG
chains (M.W. 459&#x02013;591) and incorporated TA at two different
PEG-to-TA ratios. As shown in <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>, we clearly verified that both w-MSN@PEG/TA (PEG density:
3.52 chains/nm<sup>2</sup>) and s-MSN@PEG/TA (PEG density: 1.96 chains/nm<sup>2</sup>) exhibited a brush-like configuration of PEG coating, consistent
with previous reports.<named-content content-type="bibref-group">
<xref rid="ref65" ref-type="bibr"/>,<xref rid="ref70" ref-type="bibr"/>
</named-content> We demonstrated that optimizing
short PEG density in MSNs design not only retains the inherent benefits
of PEG for in vivo applications but also preserves the functionality
of TA, thereby facilitating effective BBB crossing. Given that short
PEG chains enhance compatibility, our data show that RMSN@PEG/TA exhibited
excellent BBB penetration without causing damage to the barrier (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>c and <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>f). Moreover, compared to s-RMSN@PEG<sub>(L)</sub>/TA (PEG: M.W. 1k), s-RMSN@PEG/TA demonstrated superior
efficacy in crossing the BBB, highlighting the advantages of the short
PEG design in mice (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>k and <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>l). Overall, the small size, short-PEG/TA modification, and strong
positive charge of s-RMSN@PEG/TA contributed to its ability to cross
the BBB.</p></sec><sec id="sec5"><label>5</label><title>Conclusions</title><p>In this study, we synthesized
MSNs with controllable size, charge,
and PEG length, focusing on their ability to penetrate the BBB. Surface
modification with the positively charged quaternary ammonium molecule
TA, along with optimized short PEG density, is crucial for enabling
BBB penetration of MSNs. MSN@PEG/TA was found to have a great BBB
penetration ability without causing BBB damage. By systematically
exploring the BBB penetration capabilities of MSN@PEG/PEI and MSN@PEG/TA,
this understanding is anticipated to contribute valuable information
for the development of safe and effective drug delivery systems that
target the BBB. Additionally, we established the chick CAM as a BBB
model, which served as a versatile and accessible in vivo model due
to its natural advantages. Its applications span across angiogenesis,
tumor growth, toxicity studies, and drug testing, making it a valuable
tool in biological research, particularly in the context of cancer-
and angiogenesis-related studies. Here, we successfully demonstrated
that the chick CAM model offers refined methodologies for studying
the BBB, which may contribute to the broader perspective of future
brain-related research with the value of translational medicine.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data"><media xlink:href="am5c05429_si_001.pdf"/></supplementary-material></sec></body><back><ack id="ack1"><p>This research
was funded by Taiwan&#x02019;s National
Science and Technology Council (NSTC112-2113-M-038-004 and NSTC 113-2124-M-038-002).
This work was financially supported by the Taipei Medical University
Hospital in Taiwan (108TMU-TMUH-22). The authors would like to acknowledge
Prof. Peilin Chen (Academia Sinica of Taiwan) for supplying two-photon
confocal microscopy and Prof. Si-Han Wu (Taipei Medical University)
for his great support. The TOC graphic was created with BioRender.com.</p></ack><notes id="notes2" notes-type="data-availability"><p>Data will be
made available on request.</p></notes><notes id="notes3" notes-type="si"><p>The Supporting
Information is
available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acsami.5c05429?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acsami.5c05429</ext-link>.<list list-type="simple" id="silist"><list-item><p>Elemental analysis, fluorescence
images, 3D confocal
microscopy images, cytotoxicity, zeta potential, FTIR spectroscopy,
TGA analysis, TEM, and BET (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsami.5c05429/suppl_file/am5c05429_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes1" notes-type="author-contributions"><label>&#x02020;</label><p>C.-K.L. and Y.-S.Y. contributed equally to this
work.</p></notes><notes id="notes4" notes-type="author-contributions"><p>C.-K.L. contributed
to data curation, investigation, methodology, software, validation,
and writing original draft preparation; Y.-S.Y. contributed to conceptualization,
formal analysis, funding acquisition, project administration, resources,
investigation, supervision, and writing&#x02013;review and editing;
T.-P.L. contributed to resources, supervision, visualization, and
validation; J.-C.L. contributed to resources, supervision, visualization,
and validation; S.B. contributed to validation and writing&#x02013;original
draft; F.T. contributed to conceptualization and methodology, supervision,
and validation; Y.-P.C. contributed to conceptualization, data curation,
supervision, funding acquisition, resources, and writing&#x02013;review
and editing</p></notes><notes id="notes5" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name><surname>Bors</surname><given-names>L. A.</given-names></name><name><surname>Erd&#x00151;</surname><given-names>F.</given-names></name><article-title>Overcoming
the blood&#x02013;brain barrier. challenges
and tricks for CNS drug delivery</article-title><source>Scientia Pharmaceutica</source><year>2019</year><volume>87</volume><issue>1</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.3390/scipharm87010006</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name><surname>Upton</surname><given-names>D. H.</given-names></name><name><surname>Ung</surname><given-names>C.</given-names></name><name><surname>George</surname><given-names>S. M.</given-names></name><name><surname>Tsoli</surname><given-names>M.</given-names></name><name><surname>Kavallaris</surname><given-names>M.</given-names></name><name><surname>Ziegler</surname><given-names>D. S.</given-names></name><article-title>Challenges and opportunities
to penetrate the blood-brain
barrier for brain cancer therapy</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><issue>10</issue><fpage>4734</fpage><pub-id pub-id-type="doi">10.7150/thno.69682</pub-id><pub-id pub-id-type="pmid">35832071</pub-id>
</element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name><surname>Pardridge</surname><given-names>W. M.</given-names></name><article-title>The blood-brain
barrier: bottleneck in brain drug development</article-title><source>NeuroRx</source><year>2005</year><volume>2</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1602/neurorx.2.1.3</pub-id><pub-id pub-id-type="pmid">15717053</pub-id>
</element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Mehta</surname><given-names>A.</given-names></name><name><surname>Tong</surname><given-names>Z.</given-names></name><name><surname>Esser</surname><given-names>L.</given-names></name><name><surname>Voelcker</surname><given-names>N. H.</given-names></name><article-title>Development
of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies
and Challenges</article-title><source>Adv. Sci. (Weinh)</source><year>2021</year><volume>8</volume><issue>10</issue><elocation-id>2003937</elocation-id><pub-id pub-id-type="doi">10.1002/advs.202003937</pub-id><pub-id pub-id-type="pmid">34026447</pub-id>
</element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name><surname>Liu</surname><given-names>H.-J.</given-names></name><name><surname>Xu</surname><given-names>P.</given-names></name><article-title>Strategies to overcome/penetrate
the BBB for systemic nanoparticle
delivery to the brain/brain tumor</article-title><source>Advanced
drug delivery reviews</source><year>2022</year><volume>191</volume><elocation-id>114619</elocation-id><pub-id pub-id-type="doi">10.1016/j.addr.2022.114619</pub-id><pub-id pub-id-type="pmid">36372301</pub-id>
</element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name><surname>Meng</surname><given-names>Q.</given-names></name><name><surname>Meng</surname><given-names>H.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><article-title>Influence of nanoparticle size on
blood&#x02013;brain
barrier penetration and the accumulation of anti-seizure medicines
in the brain</article-title><source>J. Mater. Chem. B</source><year>2022</year><volume>10</volume><issue>2</issue><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1039/D1TB02015C</pub-id><pub-id pub-id-type="pmid">34897348</pub-id>
</element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Yin</surname><given-names>Z.</given-names></name><name><surname>Fu</surname><given-names>B. M.</given-names></name><article-title>Transcellular model
for neutral and charged nanoparticles across an in vitro blood&#x02013;brain
barrier</article-title><source>Cardiovascular Engineering and Technology</source><year>2020</year><volume>11</volume><fpage>607</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1007/s13239-020-00496-6</pub-id><pub-id pub-id-type="pmid">33113565</pub-id>
</element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name><surname>Ohta</surname><given-names>S.</given-names></name><name><surname>Kikuchi</surname><given-names>E.</given-names></name><name><surname>Ishijima</surname><given-names>A.</given-names></name><name><surname>Azuma</surname><given-names>T.</given-names></name><name><surname>Sakuma</surname><given-names>I.</given-names></name><name><surname>Ito</surname><given-names>T.</given-names></name><article-title>Investigating the optimum
size of nanoparticles for their delivery
into the brain assisted by focused ultrasound-induced blood&#x02013;brain
barrier opening</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>18220</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-75253-9</pub-id><pub-id pub-id-type="pmid">33106562</pub-id>
</element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name><surname>S.
Hersh</surname><given-names>D.</given-names></name><name><surname>S. Wadajkar</surname><given-names>A.</given-names></name><name><surname>B. Roberts</surname><given-names>N.</given-names></name><name><surname>G. Perez</surname><given-names>J.</given-names></name><name><surname>P. Connolly</surname><given-names>N.</given-names></name><name><surname>Frenkel</surname><given-names>V.</given-names></name><name><surname>A. Winkles</surname><given-names>J.</given-names></name><name><surname>F. Woodworth</surname><given-names>G.</given-names></name><name><surname>J. Kim</surname><given-names>A.</given-names></name><article-title>Evolving Drug Delivery Strategies
to Overcome the Blood Brain Barrier</article-title><source>Curr. Pharm.
Des</source><year>2016</year><volume>22</volume><issue>9</issue><fpage>1177</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.2174/1381612822666151221150733</pub-id><pub-id pub-id-type="pmid">26685681</pub-id>
</element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name><surname>Pardridge</surname><given-names>W. M.</given-names></name><article-title>Drug transport
across the blood-brain barrier</article-title><source>J. Cereb Blood
Flow Metab</source><year>2012</year><volume>32</volume><issue>11</issue><fpage>1959</fpage><lpage>1972</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2012.126</pub-id><pub-id pub-id-type="pmid">22929442</pub-id>
</element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name><surname>Pinheiro</surname><given-names>R. G. R.</given-names></name><name><surname>Coutinho</surname><given-names>A. J.</given-names></name><name><surname>Pinheiro</surname><given-names>M.</given-names></name><name><surname>Neves</surname><given-names>A. R.</given-names></name><article-title>Nanoparticles for
Targeted Brain Drug Delivery: What Do We Know?</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><issue>21</issue><fpage>11654</fpage><pub-id pub-id-type="doi">10.3390/ijms222111654</pub-id><pub-id pub-id-type="pmid">34769082</pub-id>
</element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Zhong</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><article-title>Endothelial glycocalyx as an important
factor in composition of blood-brain barrier</article-title><source>CNS neuroscience &#x00026; therapeutics</source><year>2021</year><volume>27</volume><issue>1</issue><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1111/cns.13560</pub-id><pub-id pub-id-type="pmid">33377610</pub-id>
</element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name><surname>Hersh</surname><given-names>A. M.</given-names></name><name><surname>Alomari</surname><given-names>S.</given-names></name><name><surname>Tyler</surname><given-names>B. M.</given-names></name><article-title>Crossing
the blood-brain barrier:
advances in nanoparticle technology for drug delivery in neuro-oncology</article-title><source>International journal of molecular sciences</source><year>2022</year><volume>23</volume><issue>8</issue><fpage>4153</fpage><pub-id pub-id-type="doi">10.3390/ijms23084153</pub-id><pub-id pub-id-type="pmid">35456971</pub-id>
</element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name><surname>Kopac</surname><given-names>T.</given-names></name><article-title>Protein corona,
understanding the nanoparticle&#x02013;protein interactions and future
perspectives: A critical review</article-title><source>Int. J. Biol.
Macromol.</source><year>2021</year><volume>169</volume><fpage>290</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.12.108</pub-id><pub-id pub-id-type="pmid">33340622</pub-id>
</element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><article-title>The interaction between nanoparticles-protein
corona complex and cells and its toxic effect on cells</article-title><source>Chemosphere</source><year>2020</year><volume>245</volume><elocation-id>125624</elocation-id><pub-id pub-id-type="doi">10.1016/j.chemosphere.2019.125624</pub-id><pub-id pub-id-type="pmid">31864050</pub-id>
</element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name><surname>Falahati</surname><given-names>M.</given-names></name><name><surname>Attar</surname><given-names>F.</given-names></name><name><surname>Sharifi</surname><given-names>M.</given-names></name><name><surname>Haertl&#x000e9;</surname><given-names>T.</given-names></name><name><surname>Berret</surname><given-names>J. F.</given-names></name><name><surname>Khan</surname><given-names>R. H.</given-names></name><name><surname>Saboury</surname><given-names>A. A.</given-names></name><article-title>A health
concern
regarding the protein corona, aggregation and disaggregation</article-title><source>Biochim Biophys Acta Gen Subj</source><year>2019</year><volume>1863</volume><issue>5</issue><fpage>971</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2019.02.012</pub-id><pub-id pub-id-type="pmid">30802594</pub-id>
</element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name><surname>Du</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Ismail</surname><given-names>M.</given-names></name><name><surname>Zheng</surname><given-names>M.</given-names></name><article-title>PEG length
effect of peptide-functional liposome for blood brain barrier (BBB)
penetration and brain targeting</article-title><source>J. Controlled
Release</source><year>2024</year><volume>372</volume><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.06.005</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name><surname>Bagchi</surname><given-names>S.</given-names></name><name><surname>Chhibber</surname><given-names>T.</given-names></name><name><surname>Lahooti</surname><given-names>B.</given-names></name><name><surname>Verma</surname><given-names>A.</given-names></name><name><surname>Borse</surname><given-names>V.</given-names></name><name><surname>Jayant</surname><given-names>R. D.</given-names></name><article-title>In-vitro blood-brain barrier models for drug screening
and permeation studies: an overview</article-title><source>Drug Design
Dev. Ther.</source><year>2019</year><fpage>3591</fpage><lpage>3605</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S218708</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name><surname>Williams-Medina</surname><given-names>A.</given-names></name><name><surname>Deblock</surname><given-names>M.</given-names></name><name><surname>Janigro</surname><given-names>D.</given-names></name><article-title>In vitro models of
the blood&#x02013;brain
barrier: Tools in translational medicine</article-title><source>Frontiers
in Medical Technology</source><year>2021</year><volume>2</volume><elocation-id>623950</elocation-id><pub-id pub-id-type="doi">10.3389/fmedt.2020.623950</pub-id><pub-id pub-id-type="pmid">35047899</pub-id>
</element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name><surname>Linville</surname><given-names>R. M.</given-names></name><name><surname>Searson</surname><given-names>P. C.</given-names></name><article-title>Next-generation in vitro blood&#x02013;brain
barrier
models: benchmarking and improving model accuracy</article-title><source>Fluids and Barriers of the CNS</source><year>2021</year><volume>18</volume><issue>1</issue><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/s12987-021-00291-y</pub-id><pub-id pub-id-type="pmid">34876171</pub-id>
</element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name><surname>Yau</surname><given-names>A.</given-names></name><name><surname>Jogdand</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><article-title>Blood-brain-barrier modeling with
tissue chips for research applications in space and on Earth</article-title><source>Space Technol.</source><year>2023</year><volume>4</volume><elocation-id>1176943</elocation-id><pub-id pub-id-type="doi">10.3389/frspt.2023.1176943</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name><surname>Hawkins</surname><given-names>B. T.</given-names></name><name><surname>Egleton</surname><given-names>R. D.</given-names></name><article-title>Pathophysiology of the blood&#x02013;brain
barrier:
animal models and methods</article-title><source>Current topics in
developmental biology</source><year>2007</year><volume>80</volume><fpage>277</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/S0070-2153(07)80007-X</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Miao</surname><given-names>X.</given-names></name><name><surname>Yi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>S. M.-Y.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><article-title>Zebrafish: A promising
in vivo model for assessing the delivery of natural products, fluorescence
dyes and drugs across the blood-brain barrier</article-title><source>Pharmacological research</source><year>2017</year><volume>125</volume><fpage>246</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2017.08.017</pub-id><pub-id pub-id-type="pmid">28867638</pub-id>
</element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name><surname>On</surname><given-names>N. H.</given-names></name><name><surname>Mitchell</surname><given-names>R.</given-names></name><name><surname>Savant</surname><given-names>S. D.</given-names></name><name><surname>Bachmeier</surname><given-names>C. J.</given-names></name><name><surname>Hatch</surname><given-names>G. M.</given-names></name><name><surname>Miller</surname><given-names>D. W.</given-names></name><article-title>Examination of blood&#x02013;brain
barrier (BBB) integrity in a mouse brain tumor model</article-title><source>Journal of neuro-oncology</source><year>2013</year><volume>111</volume><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1007/s11060-012-1006-1</pub-id><pub-id pub-id-type="pmid">23184143</pub-id>
</element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name><surname>Giusti</surname><given-names>V.</given-names></name><name><surname>Miserocchi</surname><given-names>G.</given-names></name><name><surname>Sbanchi</surname><given-names>G.</given-names></name><name><surname>Pannella</surname><given-names>M.</given-names></name><name><surname>Hattinger</surname><given-names>C. M.</given-names></name><name><surname>Cesari</surname><given-names>M.</given-names></name><name><surname>Fantoni</surname><given-names>L.</given-names></name><name><surname>Guerrieri</surname><given-names>A. N.</given-names></name><name><surname>Bellotti</surname><given-names>C.</given-names></name><name><surname>De Vita</surname><given-names>A.</given-names></name><name><surname>Spadazzi</surname><given-names>C.</given-names></name><name><surname>Donati</surname><given-names>D. M.</given-names></name><name><surname>Torsello</surname><given-names>M.</given-names></name><name><surname>Lucarelli</surname><given-names>E.</given-names></name><name><surname>Ibrahim</surname><given-names>T.</given-names></name><name><surname>Mercatali</surname><given-names>L.</given-names></name><article-title>Xenografting
Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish:
How to Boost Translational Research</article-title><source>Biomedicines</source><year>2024</year><volume>12</volume><issue>8</issue><fpage>1921</fpage><pub-id pub-id-type="doi">10.3390/biomedicines12081921</pub-id><pub-id pub-id-type="pmid">39200384</pub-id>
</element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name><surname>Butler</surname><given-names>K. S.</given-names></name><name><surname>Brinker</surname><given-names>C. J.</given-names></name><name><surname>Leong</surname><given-names>H. S.</given-names></name><article-title>Bridging
the in vitro to in vivo
gap: using the chick embryo model to accelerate nanoparticle validation
and qualification for in vivo studies</article-title><source>ACS Nano</source><year>2022</year><volume>16</volume><issue>12</issue><fpage>19626</fpage><lpage>19650</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c03990</pub-id><pub-id pub-id-type="pmid">36453753</pub-id>
</element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Shan</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><article-title>Monitoring brain development of chick embryos in vivo
using 3.0 T MRI: subdivision volume change and preliminary structural
quantification using DTI</article-title><source>BMC Dev. Biol.</source><year>2015</year><volume>15</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12861-015-0077-6</pub-id><pub-id pub-id-type="pmid">25591552</pub-id>
</element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name><surname>D&#x000ed;az-Garc&#x000ed;a</surname><given-names>D.</given-names></name><name><surname>Ferrer-Donato</surname><given-names>&#x000c1;.</given-names></name><name><surname>M&#x000e9;ndez-Arriaga</surname><given-names>J. M.</given-names></name><name><surname>Cabrera-Pinto</surname><given-names>M.</given-names></name><name><surname>D&#x000ed;az-S&#x000e1;nchez</surname><given-names>M.</given-names></name><name><surname>Prashar</surname><given-names>S.</given-names></name><name><surname>Fernandez-Martos</surname><given-names>C. M.</given-names></name><name><surname>G&#x000f3;mez-Ruiz</surname><given-names>S.</given-names></name><article-title>Design of mesoporous silica nanoparticles for the treatment
of amyotrophic lateral sclerosis (ALS) with a therapeutic cocktail
based on leptin and pioglitazone</article-title><source>ACS Biomaterials
Science &#x00026; Engineering</source><year>2022</year><volume>8</volume><issue>11</issue><fpage>4838</fpage><lpage>4849</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.2c00865</pub-id><pub-id pub-id-type="pmid">36240025</pub-id>
</element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name><surname>Ribeiro</surname><given-names>T. d. C.</given-names></name><name><surname>S&#x000e1;bio</surname><given-names>R. M.</given-names></name><name><surname>Luiz</surname><given-names>M. T.</given-names></name><name><surname>de Souza</surname><given-names>L. C.</given-names></name><name><surname>Fonseca-Santos</surname><given-names>B.</given-names></name><name><surname>Cides da Silva</surname><given-names>L. C.</given-names></name><name><surname>Fantini</surname><given-names>M. C. d. A.</given-names></name><name><surname>Planeta</surname><given-names>C. d. S.</given-names></name><name><surname>Chorilli</surname><given-names>M.</given-names></name><article-title>Curcumin-loaded
mesoporous silica
nanoparticles dispersed in thermo-responsive hydrogel as potential
Alzheimer disease therapy</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><issue>9</issue><fpage>1976</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14091976</pub-id><pub-id pub-id-type="pmid">36145723</pub-id>
</element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>James</surname><given-names>T. D.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><article-title>Benzothiazolium derivative-capped
silica nanocomposites for &#x003b2;-amyloid imaging in vivo</article-title><source>Anal. Chem.</source><year>2021</year><volume>93</volume><issue>37</issue><fpage>12617</fpage><lpage>12627</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.1c02289</pub-id><pub-id pub-id-type="pmid">34494815</pub-id>
</element-citation></ref><ref id="ref31"><mixed-citation publication-type="book" id="cit31">
<person-group person-group-type="allauthors">
<string-name>
<surname>Noureddine</surname>, <given-names>A.</given-names>
</string-name>; <string-name>
<surname>Maestas-Olguin</surname>, <given-names>A.</given-names>
</string-name>; <string-name>
<surname>Tang</surname>, <given-names>L.</given-names>
</string-name>; <string-name>
<surname>Corman-Hijar</surname>, <given-names>J. I.</given-names>
</string-name>; <string-name>
<surname>Olewine</surname>, <given-names>M.</given-names>
</string-name>; <string-name>
<surname>Krawchuck</surname>, <given-names>J. A.</given-names>
</string-name>; <string-name>
<surname>Tsala Ebode</surname>, <given-names>J.</given-names>
</string-name>; <string-name>
<surname>Edeh</surname>, <given-names>C.</given-names>
</string-name>; <string-name>
<surname>Dang</surname>, <given-names>C.</given-names>
</string-name>; <string-name>
<surname>Negrete</surname>, <given-names>O. A.</given-names>
</string-name>
</person-group>
<source>Future of Mesoporous Silica Nanoparticles
in Nanomedicine: Protocol for Reproducible Synthesis, Characterization,
Lipid Coating, and Loading of Therapeutics (Chemotherapeutic, Proteins,
siRNA and mRNA)</source>; <publisher-name>ACS Publications</publisher-name>: <year>2023</year>.</mixed-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name><surname>Maestas-Olguin</surname><given-names>A.</given-names></name><name><surname>Olewine</surname><given-names>M.</given-names></name><name><surname>Thabata</surname><given-names>S.</given-names></name><name><surname>Tsala Ebode</surname><given-names>J.</given-names></name><name><surname>Arcos</surname><given-names>M.</given-names></name><name><surname>Krawchuck</surname><given-names>J.</given-names></name><name><surname>Coker</surname><given-names>E. N.</given-names></name><name><surname>Brearley</surname><given-names>A. J.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Watt</surname><given-names>J.</given-names></name><etal/><article-title>Metallic Cation-Mediated Entrapment of Nucleic
Acids on Mesoporous Silica Surface: Application in Castration-Resistant
Prostate Cancer</article-title><source>Chem. Mater.</source><year>2023</year><volume>35</volume><issue>24</issue><fpage>10371</fpage><lpage>10383</lpage><pub-id pub-id-type="doi">10.1021/acs.chemmater.3c01174</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name><surname>Durfee</surname><given-names>P. N.</given-names></name><name><surname>Lin</surname><given-names>Y.-S.</given-names></name><name><surname>Dunphy</surname><given-names>D. R.</given-names></name><name><surname>Mu&#x000f1;iz</surname><given-names>A. J.</given-names></name><name><surname>Butler</surname><given-names>K. S.</given-names></name><name><surname>Humphrey</surname><given-names>K. R.</given-names></name><name><surname>Lokke</surname><given-names>A. J.</given-names></name><name><surname>Agola</surname><given-names>J. O.</given-names></name><name><surname>Chou</surname><given-names>S. S.</given-names></name><name><surname>Chen</surname><given-names>I. M.</given-names></name><etal/><article-title>Mesoporous Silica Nanoparticle-Supported
Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual
Leukemia Cells</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><issue>9</issue><fpage>8325</fpage><lpage>8345</lpage><pub-id pub-id-type="doi">10.1021/acsnano.6b02819</pub-id><pub-id pub-id-type="pmid">27419663</pub-id>
</element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name><surname>Townson</surname><given-names>J. L.</given-names></name><name><surname>Lin</surname><given-names>Y.-S.</given-names></name><name><surname>Agola</surname><given-names>J. O.</given-names></name><name><surname>Carnes</surname><given-names>E. C.</given-names></name><name><surname>Leong</surname><given-names>H. S.</given-names></name><name><surname>Lewis</surname><given-names>J. D.</given-names></name><name><surname>Haynes</surname><given-names>C. L.</given-names></name><name><surname>Brinker</surname><given-names>C. J.</given-names></name><article-title>Re-examining the
Size/Charge Paradigm: Differing in Vivo Characteristics of Size- and
Charge-Matched Mesoporous Silica Nanoparticles</article-title><source>J. Am. Chem. Soc.</source><year>2013</year><volume>135</volume><issue>43</issue><fpage>16030</fpage><lpage>16033</lpage><pub-id pub-id-type="doi">10.1021/ja4082414</pub-id><pub-id pub-id-type="pmid">24107191</pub-id>
</element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name><surname>Ribatti</surname><given-names>D.</given-names></name><article-title>The chick
embryo chorioallantoic membrane (CAM) assay</article-title><source>Reproductive toxicology</source><year>2017</year><volume>70</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.reprotox.2016.11.004</pub-id><pub-id pub-id-type="pmid">27832950</pub-id>
</element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name><surname>Ribatti</surname><given-names>D.</given-names></name><article-title>The chick
embryo chorioallantoic membrane (CAM). A multifaceted experimental
model</article-title><source>Mechanisms of development</source><year>2016</year><volume>141</volume><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.mod.2016.05.003</pub-id><pub-id pub-id-type="pmid">27178379</pub-id>
</element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name><surname>Raymond</surname><given-names>S. B.</given-names></name><name><surname>Treat</surname><given-names>L. H.</given-names></name><name><surname>Dewey</surname><given-names>J. D.</given-names></name><name><surname>McDannold</surname><given-names>N. J.</given-names></name><name><surname>Hynynen</surname><given-names>K.</given-names></name><name><surname>Bacskai</surname><given-names>B. J.</given-names></name><article-title>Ultrasound enhanced
delivery of molecular
imaging and therapeutic agents in Alzheimer&#x02019;s disease mouse
models</article-title><source>PloS one</source><year>2008</year><volume>3</volume><issue>5</issue><elocation-id>e2175</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002175</pub-id><pub-id pub-id-type="pmid">18478109</pub-id>
</element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name><surname>Macklin</surname><given-names>C. C.</given-names></name><name><surname>Macklin</surname><given-names>M. T.</given-names></name><article-title>A Study of Brain
Repair in the Rat by the Use of Trypan
Blue: With Special Reference to the Vital Staining of the Macrophages</article-title><source>Archives of Neurology &#x00026; Psychiatry</source><year>1920</year><volume>3</volume><issue>4</issue><fpage>353</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1001/archneurpsyc.1920.02180160002001</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name><surname>Koffie</surname><given-names>R. M.</given-names></name><name><surname>Farrar</surname><given-names>C. T.</given-names></name><name><surname>Saidi</surname><given-names>L.-J.</given-names></name><name><surname>William</surname><given-names>C. M.</given-names></name><name><surname>Hyman</surname><given-names>B. T.</given-names></name><name><surname>Spires-Jones</surname><given-names>T. L.</given-names></name><article-title>Nanoparticles
enhance brain delivery of blood&#x02013;brain
barrier-impermeable probes for in vivo optical and magnetic resonance
imaging</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2011</year><volume>108</volume><issue>46</issue><fpage>18837</fpage><lpage>18842</lpage><pub-id pub-id-type="doi">10.1073/pnas.1111405108</pub-id><pub-id pub-id-type="pmid">22065785</pub-id>
</element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name><surname>Reynolds</surname><given-names>D.</given-names></name><name><surname>Morton</surname><given-names>A.</given-names></name><article-title>Changes in blood&#x02013;brain barrier permeability
following neurotoxic lesions of rat brain can be visualised with trypan
blue</article-title><source>Journal of neuroscience methods</source><year>1998</year><volume>79</volume><issue>1</issue><fpage>115</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/S0165-0270(97)00168-4</pub-id><pub-id pub-id-type="pmid">9531467</pub-id>
</element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name><surname>Guo</surname><given-names>R.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Shen</surname><given-names>N.</given-names></name><name><surname>Mo</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><article-title>Hydrogen sulfide
attenuates doxorubicin-induced cardiotoxicity by
inhibition of the p38 MAPK pathway in H9c2 cells</article-title><source>International journal of molecular medicine</source><year>2013</year><volume>31</volume><issue>3</issue><fpage>644</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2013.1246</pub-id><pub-id pub-id-type="pmid">23338126</pub-id>
</element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Qian</surname><given-names>W.</given-names></name><name><surname>Rui</surname><given-names>T.</given-names></name><article-title>Role of HMGB1
in doxorubicin-induced myocardial apoptosis and its regulation pathway</article-title><source>Basic Res. Cardiol.</source><year>2012</year><volume>107</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s00395-012-0267-3</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name><surname>Lin</surname><given-names>Y.-S.</given-names></name><name><surname>Haynes</surname><given-names>C. L.</given-names></name><article-title>Impacts of mesoporous
silica nanoparticle size, pore
ordering, and pore integrity on hemolytic activity</article-title><source>J. Am. Chem. Soc.</source><year>2010</year><volume>132</volume><issue>13</issue><fpage>4834</fpage><lpage>4842</lpage><pub-id pub-id-type="doi">10.1021/ja910846q</pub-id><pub-id pub-id-type="pmid">20230032</pub-id>
</element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><article-title>Polyethyleneimine-based
drug delivery systems for cancer theranostics</article-title><source>Journal of Functional Biomaterials</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>12</fpage><pub-id pub-id-type="doi">10.3390/jfb14010012</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name><surname>Wen</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>F.</given-names></name><name><surname>Shen</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><article-title>Surface modification
and PEGylation of branched polyethyleneimine for improved biocompatibility</article-title><source>J. Appl. Polym. Sci.</source><year>2013</year><volume>128</volume><issue>6</issue><fpage>3807</fpage><lpage>3813</lpage><pub-id pub-id-type="doi">10.1002/app.38444</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name><surname>Wiwatchaitawee</surname><given-names>K.</given-names></name><name><surname>Ebeid</surname><given-names>K.</given-names></name><name><surname>Quarterman</surname><given-names>J. C.</given-names></name><name><surname>Naguib</surname><given-names>Y.</given-names></name><name><surname>Ali</surname><given-names>M. D. Y.</given-names></name><name><surname>Oliva</surname><given-names>C.</given-names></name><name><surname>Griguer</surname><given-names>C.</given-names></name><name><surname>Salem</surname><given-names>A. K.</given-names></name><article-title>Surface Modification
of Nanoparticles Enhances Drug Delivery to the Brain and Improves
Survival in a Glioblastoma Multiforme Murine Model</article-title><source>Bioconjugate Chem.</source><year>2022</year><volume>33</volume><issue>11</issue><fpage>1957</fpage><lpage>1972</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.1c00479</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name><surname>Fabiano</surname><given-names>A.</given-names></name><name><surname>Beconcini</surname><given-names>D.</given-names></name><name><surname>Migone</surname><given-names>C.</given-names></name><name><surname>Piras</surname><given-names>A. M.</given-names></name><name><surname>Zambito</surname><given-names>Y.</given-names></name><article-title>Quaternary
ammonium chitosans: The importance of the positive fixed charge of
the drug delivery systems</article-title><source>International Journal
of Molecular Sciences</source><year>2020</year><volume>21</volume><issue>18</issue><fpage>6617</fpage><pub-id pub-id-type="doi">10.3390/ijms21186617</pub-id><pub-id pub-id-type="pmid">32927715</pub-id>
</element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name><surname>Chen</surname><given-names>Z. A.</given-names></name><name><surname>Wu</surname><given-names>C. H.</given-names></name><name><surname>Wu</surname><given-names>S. H.</given-names></name><name><surname>Huang</surname><given-names>C. Y.</given-names></name><name><surname>Mou</surname><given-names>C. Y.</given-names></name><name><surname>Wei</surname><given-names>K. C.</given-names></name><name><surname>Yen</surname><given-names>Y.</given-names></name><name><surname>Chien</surname><given-names>I. T.</given-names></name><name><surname>Runa</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Y. P.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><article-title>Receptor Ligand-Free Mesoporous Silica
Nanoparticles: A Streamlined Strategy for Targeted Drug Delivery across
the Blood&#x02013;Brain Barrier</article-title><source>ACS Nano</source><year>2024</year><volume>18</volume><fpage>12716</fpage><lpage>12736</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c08993</pub-id><pub-id pub-id-type="pmid">38718220</pub-id>
</element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name><surname>Ashrafizadeh</surname><given-names>M.</given-names></name><name><surname>Hushmandi</surname><given-names>K.</given-names></name><name><surname>Mirzaei</surname><given-names>S.</given-names></name><name><surname>Bokaie</surname><given-names>S.</given-names></name><name><surname>Bigham</surname><given-names>A.</given-names></name><name><surname>Makvandi</surname><given-names>P.</given-names></name><name><surname>Rabiee</surname><given-names>N.</given-names></name><name><surname>Thakur</surname><given-names>V. K.</given-names></name><name><surname>Kumar</surname><given-names>A. P.</given-names></name><name><surname>Sharifi</surname><given-names>E.</given-names></name><name><surname>Varma</surname><given-names>R. S.</given-names></name><name><surname>Aref</surname><given-names>A. R.</given-names></name><name><surname>Wojnilowicz</surname><given-names>M.</given-names></name><name><surname>Zarrabi</surname><given-names>A.</given-names></name><name><surname>Karimi-Maleh</surname><given-names>H.</given-names></name><name><surname>Voelcker</surname><given-names>N. H.</given-names></name><name><surname>Mostafavi</surname><given-names>E.</given-names></name><name><surname>Orive</surname><given-names>G.</given-names></name><article-title>Chitosan-based nanoscale
systems for doxorubicin delivery: Exploring
biomedical application in cancer therapy</article-title><source>Bioeng.
Transl. Med.</source><year>2023</year><volume>8</volume><issue>1</issue><elocation-id>e10325</elocation-id><pub-id pub-id-type="doi">10.1002/btm2.10325</pub-id><pub-id pub-id-type="pmid">36684100</pub-id>
</element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name><surname>Rungnim</surname><given-names>C.</given-names></name><name><surname>Rungrotmongkol</surname><given-names>T.</given-names></name><name><surname>Poo-Arporn</surname><given-names>R. P.</given-names></name><article-title>pH-controlled doxorubicin anticancer
loading and release from carbon nanotube noncovalently modified by
chitosan: MD simulations</article-title><source>Journal of Molecular
Graphics and Modelling</source><year>2016</year><volume>70</volume><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jmgm.2016.09.011</pub-id><pub-id pub-id-type="pmid">27677150</pub-id>
</element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name><surname>Breschi</surname><given-names>A.</given-names></name><name><surname>Gingeras</surname><given-names>T. R.</given-names></name><name><surname>Guig&#x000f3;</surname><given-names>R.</given-names></name><article-title>Comparative
transcriptomics in human
and mouse</article-title><source>Nat. Rev. Genet.</source><year>2017</year><volume>18</volume><issue>7</issue><fpage>425</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1038/nrg.2017.19</pub-id><pub-id pub-id-type="pmid">28479595</pub-id>
</element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Yu</surname><given-names>G.-Y.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>C.</given-names></name><name><surname>Kurihara</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.-F.</given-names></name><name><surname>So</surname><given-names>K.-F.</given-names></name><name><surname>He</surname><given-names>R.-R.</given-names></name><article-title>Fostering
efficacy
and toxicity evaluation of traditional Chinese medicine and natural
products: Chick embryo as a high throughput model bridging in vitro
and in vivo studies</article-title><source>Pharmacol. Res.</source><year>2018</year><volume>133</volume><fpage>21</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.04.011</pub-id><pub-id pub-id-type="pmid">29679640</pub-id>
</element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name><surname>Alla</surname><given-names>R. K.</given-names></name><name><surname>Konakanchi</surname><given-names>A.</given-names></name><name><surname>Nallakunta</surname><given-names>R.</given-names></name><name><surname>A. V.</surname><given-names>R.</given-names></name><name><surname>M. C.</surname><given-names>S. S.</given-names></name><name><surname>Mantena</surname><given-names>S. R.</given-names></name><article-title>The Zebrafish
(Danio rerio): A Dynamic Model Organism
for Scientific Research</article-title><source>Uttar Pradesh Journal
of Zoology</source><year>2024</year><volume>45</volume><issue>15</issue><fpage>526</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.56557/upjoz/2024/v45i154269</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name><surname>Umans</surname><given-names>R. A.</given-names></name><name><surname>Taylor</surname><given-names>M. R.</given-names></name><article-title>Zebrafish as a model
to study drug transporters at
the blood-brain barrier</article-title><source>Clin Pharmacol Ther</source><year>2012</year><volume>92</volume><issue>5</issue><fpage>567</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1038/clpt.2012.168</pub-id><pub-id pub-id-type="pmid">23047649</pub-id>
</element-citation></ref><ref id="ref55"><element-citation publication-type="journal" id="cit55"><name><surname>Hossay</surname><given-names>C.</given-names></name><name><surname>Cacciottola</surname><given-names>L.</given-names></name><name><surname>Storder</surname><given-names>S.</given-names></name><name><surname>Van Kerk</surname><given-names>O.</given-names></name><name><surname>Dolmans</surname><given-names>M. M.</given-names></name><article-title>The Chick
Chorioallantoic Membrane (CAM) Model as a Tool to Study Ovarian Tissue
Transplantation</article-title><source>JoVE</source><year>2023</year><volume>196</volume><elocation-id>e64867</elocation-id><pub-id pub-id-type="doi">10.3791/64867</pub-id></element-citation></ref><ref id="ref56"><mixed-citation publication-type="book" id="cit56">
<person-group person-group-type="allauthors">
<string-name>
<surname>Revi</surname>, <given-names>N.</given-names>
</string-name>; <string-name>
<surname>Oladejo</surname>, <given-names>O. D.</given-names>
</string-name>; <string-name>
<surname>Bijukumar</surname>, <given-names>D.</given-names>
</string-name>
</person-group>
<article-title>In Vitro, In Vivo
and Ex Vivo Models for Toxicity Evaluation of Nanoparticles: Advantages
and Disadvantages</article-title>. <source>Toxicity of Nanoparticles-Recent
Advances and New Perspectives</source>; <publisher-name>IntechOpen</publisher-name>
<year>2023</year>.</mixed-citation></ref><ref id="ref57"><element-citation publication-type="journal" id="cit57"><name><surname>Sarogni</surname><given-names>P.</given-names></name><name><surname>Mapanao</surname><given-names>A. K.</given-names></name><name><surname>Gonnelli</surname><given-names>A.</given-names></name><name><surname>Ermini</surname><given-names>M. L.</given-names></name><name><surname>Marchetti</surname><given-names>S.</given-names></name><name><surname>Kusmic</surname><given-names>C.</given-names></name><name><surname>Paiar</surname><given-names>F.</given-names></name><name><surname>Voliani</surname><given-names>V.</given-names></name><article-title>Chorioallantoic membrane
tumor models highlight the effects of cisplatin compounds in oral
carcinoma treatment</article-title><source>IScience</source><year>2022</year><volume>25</volume><issue>3</issue><elocation-id>103980</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2022.103980</pub-id><pub-id pub-id-type="pmid">35310338</pub-id>
</element-citation></ref><ref id="ref58"><element-citation publication-type="journal" id="cit58"><name><surname>Santhosh
Kumar</surname><given-names>Y.</given-names></name><name><surname>Thangam</surname><given-names>C.</given-names></name><name><surname>Cyril</surname><given-names>R.</given-names></name><name><surname>Murugan</surname><given-names>H.</given-names></name><name><surname>Selvaraj</surname><given-names>S.</given-names></name><name><surname>Langeswaran</surname><given-names>K.</given-names></name><article-title>Anti-angiogenic activity of nano
naringenin on chick chorioallantoic membrane model</article-title><source>J. Pharm. Negat. Results</source><year>2022</year><fpage>4038</fpage><lpage>4047</lpage></element-citation></ref><ref id="ref59"><element-citation publication-type="journal" id="cit59"><name><surname>Sanchez-Cano</surname><given-names>C.</given-names></name><name><surname>Carril</surname><given-names>M.</given-names></name><article-title>Recent developments
in the design of non-biofouling
coatings for nanoparticles and surfaces</article-title><source>International
journal of molecular sciences</source><year>2020</year><volume>21</volume><issue>3</issue><fpage>1007</fpage><pub-id pub-id-type="doi">10.3390/ijms21031007</pub-id><pub-id pub-id-type="pmid">32028729</pub-id>
</element-citation></ref><ref id="ref60"><element-citation publication-type="journal" id="cit60"><name><surname>Fam</surname><given-names>S. Y.</given-names></name><name><surname>Chee</surname><given-names>C. F.</given-names></name><name><surname>Yong</surname><given-names>C. Y.</given-names></name><name><surname>Ho</surname><given-names>K. L.</given-names></name><name><surname>Mariatulqabtiah</surname><given-names>A. R.</given-names></name><name><surname>Tan</surname><given-names>W. S.</given-names></name><article-title>Stealth coating of nanoparticles in drug-delivery systems</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><issue>4</issue><fpage>787</fpage><pub-id pub-id-type="doi">10.3390/nano10040787</pub-id><pub-id pub-id-type="pmid">32325941</pub-id>
</element-citation></ref><ref id="ref61"><element-citation publication-type="journal" id="cit61"><name><surname>Chithrani</surname><given-names>D. B.</given-names></name><article-title>Polyethylene
glycol density and length affects nanoparticle uptake by cancer cells</article-title><source>J. Nanomed. Res.</source><year>2014</year><volume>1</volume><issue>00006</issue><fpage>8</fpage><pub-id pub-id-type="doi">10.15406/jnmr.2014.01.00006</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal" id="cit62"><name><surname>Partikel</surname><given-names>K.</given-names></name><name><surname>Korte</surname><given-names>R.</given-names></name><name><surname>Stein</surname><given-names>N. C.</given-names></name><name><surname>Mulac</surname><given-names>D.</given-names></name><name><surname>Herrmann</surname><given-names>F. C.</given-names></name><name><surname>Humpf</surname><given-names>H.-U.</given-names></name><name><surname>Langer</surname><given-names>K.</given-names></name><article-title>Effect of
nanoparticle size and PEGylation
on the protein corona of PLGA nanoparticles</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2019</year><volume>141</volume><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2019.05.006</pub-id><pub-id pub-id-type="pmid">31082511</pub-id>
</element-citation></ref><ref id="ref63"><element-citation publication-type="journal" id="cit63"><name><surname>Ebara</surname><given-names>M.</given-names></name><name><surname>Yamato</surname><given-names>M.</given-names></name><name><surname>Aoyagi</surname><given-names>T.</given-names></name><name><surname>Kikuchi</surname><given-names>A.</given-names></name><name><surname>Sakai</surname><given-names>K.</given-names></name><name><surname>Okano</surname><given-names>T.</given-names></name><article-title>The effect of extensible PEG tethers
on shielding between grafted
thermo-responsive polymer chains and integrin&#x02013;RGD binding</article-title><source>Biomaterials</source><year>2008</year><volume>29</volume><issue>27</issue><fpage>3650</fpage><lpage>3655</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2008.05.030</pub-id><pub-id pub-id-type="pmid">18582933</pub-id>
</element-citation></ref><ref id="ref64"><element-citation publication-type="journal" id="cit64"><name><surname>Cruz</surname><given-names>L. J.</given-names></name><name><surname>Tacken</surname><given-names>P. J.</given-names></name><name><surname>Fokkink</surname><given-names>R.</given-names></name><name><surname>Figdor</surname><given-names>C. G.</given-names></name><article-title>The influence of
PEG chain length and targeting moiety on antibody-mediated delivery
of nanoparticle vaccines to human dendritic cells</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><issue>28</issue><fpage>6791</fpage><lpage>6803</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.04.082</pub-id><pub-id pub-id-type="pmid">21724247</pub-id>
</element-citation></ref><ref id="ref65"><element-citation publication-type="journal" id="cit65"><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Tang</surname><given-names>S.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><article-title>Effects of polyethylene glycol on
the surface of nanoparticles for
targeted drug delivery</article-title><source>Nanoscale</source><year>2021</year><volume>13</volume><issue>24</issue><fpage>10748</fpage><lpage>10764</lpage><pub-id pub-id-type="doi">10.1039/D1NR02065J</pub-id><pub-id pub-id-type="pmid">34132312</pub-id>
</element-citation></ref><ref id="ref66"><element-citation publication-type="journal" id="cit66"><name><surname>Labouta</surname><given-names>H.
I.</given-names></name><name><surname>Gomez-Garcia</surname><given-names>M. J.</given-names></name><name><surname>Sarsons</surname><given-names>C. D.</given-names></name><name><surname>Nguyen</surname><given-names>T.</given-names></name><name><surname>Kennard</surname><given-names>J.</given-names></name><name><surname>Ngo</surname><given-names>W.</given-names></name><name><surname>Terefe</surname><given-names>K.</given-names></name><name><surname>Iragorri</surname><given-names>N.</given-names></name><name><surname>Lai</surname><given-names>P.</given-names></name><name><surname>Rinker</surname><given-names>K. D.</given-names></name><name><surname>Cramb</surname><given-names>D. T.</given-names></name><article-title>Surface-grafted polyethylene glycol conformation impacts
the transport of PEG-functionalized liposomes through a tumour extracellular
matrix model</article-title><source>RSC Adv.</source><year>2018</year><volume>8</volume><issue>14</issue><fpage>7697</fpage><lpage>7708</lpage><pub-id pub-id-type="doi">10.1039/C7RA13438J</pub-id><pub-id pub-id-type="pmid">35539117</pub-id>
</element-citation></ref><ref id="ref67"><element-citation publication-type="journal" id="cit67"><name><surname>Walkey</surname><given-names>C. D.</given-names></name><name><surname>Olsen</surname><given-names>J. B.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Emili</surname><given-names>A.</given-names></name><name><surname>Chan</surname><given-names>W. C.</given-names></name><article-title>Nanoparticle
size and surface chemistry determine serum protein adsorption and
macrophage uptake</article-title><source>J. Am. Chem. Soc.</source><year>2012</year><volume>134</volume><issue>4</issue><fpage>2139</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.1021/ja2084338</pub-id><pub-id pub-id-type="pmid">22191645</pub-id>
</element-citation></ref><ref id="ref68"><element-citation publication-type="journal" id="cit68"><name><surname>Perry</surname><given-names>J. L.</given-names></name><name><surname>Reuter</surname><given-names>K. G.</given-names></name><name><surname>Kai</surname><given-names>M. P.</given-names></name><name><surname>Herlihy</surname><given-names>K. P.</given-names></name><name><surname>Jones</surname><given-names>S. W.</given-names></name><name><surname>Luft</surname><given-names>J. C.</given-names></name><name><surname>Napier</surname><given-names>M.</given-names></name><name><surname>Bear</surname><given-names>J. E.</given-names></name><name><surname>DeSimone</surname><given-names>J. M.</given-names></name><article-title>PEGylated
PRINT nanoparticles: the impact of PEG density on protein binding,
macrophage association, biodistribution, and pharmacokinetics</article-title><source>Nano Lett.</source><year>2012</year><volume>12</volume><issue>10</issue><fpage>5304</fpage><lpage>5310</lpage><pub-id pub-id-type="doi">10.1021/nl302638g</pub-id><pub-id pub-id-type="pmid">22920324</pub-id>
</element-citation></ref><ref id="ref69"><element-citation publication-type="journal" id="cit69"><name><surname>Peracchia</surname><given-names>M. T.</given-names></name><name><surname>Vauthier</surname><given-names>C.</given-names></name><name><surname>Passirani</surname><given-names>C.</given-names></name><name><surname>Couvreur</surname><given-names>P.</given-names></name><name><surname>Labarre</surname><given-names>D.</given-names></name><article-title>Complement
consumption by poly (ethylene glycol) in different conformations chemically
coupled to poly (isobutyl 2-cyanoacrylate) nanoparticles</article-title><source>Life Sciences</source><year>1997</year><volume>61</volume><issue>7</issue><fpage>749</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(97)00539-0</pub-id><pub-id pub-id-type="pmid">9252249</pub-id>
</element-citation></ref><ref id="ref70"><element-citation publication-type="journal" id="cit70"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Simon</surname><given-names>J.</given-names></name><name><surname>Pa&#x000df;lick</surname><given-names>D.</given-names></name><name><surname>Frey</surname><given-names>M.-L.</given-names></name><name><surname>Wagner</surname><given-names>M.</given-names></name><name><surname>Mail&#x000e4;nder</surname><given-names>V.</given-names></name><name><surname>Crespy</surname><given-names>D.</given-names></name><name><surname>Landfester</surname><given-names>K.</given-names></name><article-title>Brush conformation of polyethylene
glycol determines the stealth effect of nanocarriers in the low protein
adsorption regime</article-title><source>Nano Lett.</source><year>2021</year><volume>21</volume><issue>4</issue><fpage>1591</fpage><lpage>1598</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.0c03756</pub-id><pub-id pub-id-type="pmid">33560851</pub-id>
</element-citation></ref></ref-list></back></article><!--Stylesheet Name and Version:openaccess.xsl v2.1
Date and Time: 2025-05-23T06:15:41.95-04:00
XML Format:jats-->